Express Mail Label No. EL777534031US

UTILITY PATENT APPLICATION TRANSMITTAL
(Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. DEX-0117
Total Pages in this Submission

TO THE ASSISTANT COMMISSIONER FOR PATENTS
Box Patent Application
Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

A NOVEL METHOD OF DIAGNOSING, MONITORING, STAGING, IMAGING AND TREATING BREAST CANCER

and invented by:

Salceda et al.

If a CONTINUATION APPLICATION, *check appropriate box and supply the requisite information:*

☐ **Continuation** ☐ **Divisional** ☐ **Continuation-in-part (CIP)** of prior application No.: _____

Which is a:

☐ **Continuation** ☐ **Divisional** ☐ **Continuation-in-part (CIP)** of prior application No.: _____

Which is a:

☐ **Continuation** ☐ **Divisional** ☐ **Continuation-in-part (CIP)** of prior application No.: _____

Enclosed are:

Application Elements

1. ☒ Filing fee as calculated and transmitted as described below
2. ☒ Specification having **47** pages and including the following:
 - a. ☒ Descriptive Title of the Invention
 - b. ☒ Cross References to Related Applications *(if applicable)*
 - c. ☐ Statement Regarding Federally-sponsored Research/Development *(if applicable)*
 - d. ☐ Reference to Microfiche Appendix *(if applicable)*
 - e. ☒ Background of the Invention
 - f. ☒ Brief Summary of the Invention
 - g. ☐ Brief Description of the Drawings *(if drawings filed)*
 - h. ☒ Detailed Description
 - i. ☒ Claim(s) as Classified Below
 - j. ☒ Abstract of the Disclosure

UTILITY PATENT APPLICATION TRANSMITTAL
(Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. DEX-0117
Total Pages in this Submission

Application Elements (Continued)

3. ☐ Drawing(s) *(when necessary as prescribed by 35 USC 113)*

 a. ☐ Formal b. ☐ Informal Number of Sheets _____

4. ☒ Oath or Declaration

 a. ☐ Newly executed *(original or copy)* ☒ Unexecuted

 b. ☐ Copy from a prior application (37 CFR 1.63(d)) *(for continuation/divisional application only)*

 c. ☒ With Power of Attorney ☐ Without Power of Attorney

 d. ☐ *DELETION OF INVENTOR(S)*
 Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).

5. ☐ Incorporation By Reference *(usable if Box 4b is checked)*
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

6. ☐ Computer Program in Microfiche

7. ☒ Genetic Sequence Submission *(if applicable, all must be included)*

 a. ☒ Paper Copy

 b. ☒ Computer Readable Copy

 c. ☒ Statement Verifying Identical Paper and Computer Readable Copy

Accompanying Application Parts

8. ☐ Assignment Papers *(cover sheet & documents)*

9. ☐ 37 CFR 3.73(b) Statement *(when there is an assignee)*

10. ☐ English Translation Document *(if applicable)*

11. ☐ Information Disclosure Statement/PTO-1449 ☐ Copies of IDS Citations

12. ☐ Preliminary Amendment

13. ☒ Acknowledgment postcard

14. ☒ Certificate of Mailing

 ☐ First Class ☒ Express Mail *(Specify Label No.):* **EL777534031US**

UTILITY PATENT APPLICATION TRANSMITTAL
(Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. DEX-0117
Total Pages in this Submission

Accompanying Application Parts (Continued)

15. ☐ Certified Copy of Priority Document(s) *(if foreign priority is claimed)*

16. ☐ Small Entity Statement(s) - Specify Number of Statements Submitted: _____

17. ☐ Additional Enclosures *(please identify below):*

Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)

18. ☐ Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.

Warning

An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

UTILITY PATENT APPLICATION TRANSMITTAL
(Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. DEX-0117
Total Pages in this Submission

Fee Calculation and Transmittal

CLAIMS AS FILED

For	#Filed	#Allowed	#Extra		Rate	Fee
Total Claims	17	- 20 =	0	x	$9.00	$0.00
Indep. Claims	11	- 3 =	8	x	$40.00	$320.00
Multiple Dependent Claims (check if applicable) ☐						$0.00
					BASIC FEE	$355.00
OTHER FEE *(specify purpose)* _____						$0.00
					TOTAL FILING FEE	$675.00

☒ A check in the amount of **$675.00** to cover the filing fee is enclosed.

☒ The Commissioner is hereby authorized to charge and credit Deposit Account No. **50-1619** as described below. A duplicate copy of this sheet is enclosed.

- ☐ Charge the amount of _____ as filing fee.
- ☒ Credit any overpayment.
- ☒ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
- ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).

Dated: **November 22, 2000**

/Kathleen A. Tyrrell/
Signature

Kathleen A. Tyrrell
Reg. No. 38,350
Licata & Tyrrell P.C.
66 E. Main Street
Marlton, NJ 08053
Tel: 856-810-1515
Fax: 856-810-1454

26259
PATENT TRADEMARK OFFICE

cc:

DEX-0117

jc815 U.S. PTO
09/721183
11/22/00

CERTIFICATE OF EXPRESS MAILING

"Express Mail" Label No. EL777534031US
Date of Deposit **November 22, 2000**

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R 1.10 on the date indicated above and is addressed to the "BOX SEQUENCE", Assistant Commissioner for Patents, Washington, D.C. 20231.

1) Patent Application Transmittal Letter (2 copies);

2) Application consisting of 47 pages of Specification, including four (4) pages of Claims, and one (1) page of Abstract;

3) Return Post Card;

5) Check in the amount of $675.00;

7) Unexecuted Declaration and Power of Attorney;

8) Statement to Support Filing and Submission in Accordance with 37 C.F.R. §§1.821-1.825;

9) Sequence listing; and

10) Diskette containing computer readable copy of Sequence Listing.

DEX-0117

Kathleen A. Tyrrell
KATHLEEN A. TYRRELL

A NOVEL METHOD OF DIAGNOSING, MONITORING, STAGING, IMAGING AND TREATING BREAST CANCER

INTRODUCTION

This application claims the benefit of priority from U.S. provisional application Serial No. 60/166,973, filed November 23, 1999.

FIELD OF THE INVENTION

This invention relates, in part, to newly identified breast cancer specific genes and assays for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating cancers, particularly breast cancer.

BACKGROUND OF THE INVENTION

It is estimated that one out of every nine women in America will develop breast cancer sometime during her life based on a lifespan of 85 years. Annually, over 180,000 women in the United States are diagnosed with breast cancer and approximately 46,000 die from this disease. Every woman is at risk for breast cancer. However, a woman's chances of developing breast cancer increase as she grows older; 80 percent of all cancers are found in women over the age of 50. There are also several risk factors that can increase a woman's chances of developing breast cancer. These include a family history of breast cancer, having no children or the first child after the age of 30, and an early start of menstruation. However, more than 70 percent of women who develop breast cancer have no known risk factors. Less than 10 percent of breast cancer cases are thought to be related to the BRCA1 gene discovered in 1994. Researchers are now investigating the role of other factors such as nutrition,

alcohol, exercise, smoking, and oral contraceptives in development of this gynecologic cancer. Mammograms, or special x-rays of the breast, can detect more than 90 percent of all cancers.

Procedures used for detecting, diagnosing, monitoring, staging, and prognosticating breast cancer are of critical importance to the outcome of the patient. Patients diagnosed early generally have a much greater five-year survival rate as compared to the survival rate for patients diagnosed with distant metastasized breast cancer. New diagnostic methods which are more sensitive and specific for detecting early breast cancer are clearly needed.

Breast cancer patients are closely monitored following initial therapy and during adjuvant therapy to determine response to therapy and to detect persistent or recurrent disease or metastasis. Thus, there is also clearly a need for cancer markers which are more sensitive and specific in detecting breast cancer recurrence.

Another important step in managing breast cancer is to determine the stage of the patient's disease. Stage determination has potential prognostic value and provides criteria for designing optimal therapy. Generally, pathological staging of cancer is preferable over clinical staging because the former gives a more accurate prognosis. However, clinical staging would be preferred were it at least as accurate as pathological staging because it does not depend on an invasive procedure to obtain tissue for pathological evaluation. Staging of cancer would be improved by detecting new markers in cells, tissues or bodily fluids which could differentiate between different stages of invasion.

New breast cancer specific genes, referred to herein as BCSGs, have now been identified for use in diagnosing, monitoring, staging, imaging and treating cancers, and in particular breast cancer. Accordingly, the present invention relates to new methods for detecting, diagnosing, monitoring,

staging, prognosticating, *in vivo* imaging and treating cancer via a BCSG. BCSG refers, among other things, to native proteins expressed by the genes comprising the polynucleotide sequences of BCSG-1 or Gene ID 332369 (SEQ ID NO: 1), BCSG-2 or Gene ID 480489 (SEQ ID NO:2 or 18), BCSG-3 or Gene ID 274731 (SEQ ID NO:3 or 20), BCSG-4 or Gene ID 173388 (SEQ ID NO:4) or BCSG-5 or Clone ID 3040232, Gene ID 411152 (SEQ ID NO:5). Exemplary proteins expressed by genes BCSG-2 and BCSG-3 are depicted herein as SEQ ID NO:19 and SEQ ID NO:21. By "BCSG" it is also meant herein variant polynucleotides which, due to degeneracy in genetic coding, comprise variations in nucleotide sequence as compared to SEQ ID NO: 1, 2, 3, 4, 5, 18 or 20 but which still encode the same proteins. In the alternative, what is meant by BCSG as used herein, means the native mRNAs encoded by the genes comprising BCSG-1 or Gene ID 332369 (SEQ ID NO: 1), BCSG-2 or Gene ID 480489 (SEQ ID NO:2 or 18), BCSG-3 or Gene ID 274731 (SEQ ID NO:3 or 20), BCSG-4 or Gene ID 173388 (SEQ ID NO:4) or BCSG-5 or Clone ID 3040232, Gene ID 411152 (SEQ ID NO:5) or it can refer to the actual genes comprising BCSG-1 or Gene ID 332369 (SEQ ID NO: 1), BCSG-2 or Gene ID 480489 (SEQ ID NO:2 or 18), BCSG-3 or Gene ID 274731 (SEQ ID NO:3 or 20), BCSG-4 or Gene ID 173388 (SEQ ID NO:4) or BCSG-5 or Clone ID 3040232, Gene ID 411152 (SEQ ID NO:5), or levels of polynucleotides which are capable of hybridizing under stringent conditions to the antisense sequences of SEQ ID NO: 1, 2, 3, 4, 5, 18 or 20.

Other objects, features, advantages and aspects of the present invention will become apparent to those of skill in the art from the following description. It should be understood, however, that the following description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only. Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those

skilled in the art from reading the following description and from reading the other parts of the present disclosure.

SUMMARY OF THE INVENTION

Toward these ends, and others, it is an object of the present invention to provide BCSGs comprising a polynucleotide of SEQ ID NO:1, 2, 3, 4, 5, 18 or 20 or a variant thereof, a protein expressed by a polynucleotide of SEQ ID NO:1, 2, 3, 4, 5, 18 or 20 or variant thereof which expresses the protein; or a polynucleotide which is capable of hybridizing under stringent conditions to the antisense sequence of SEQ ID NO: 1, 2, 3, 4, 5, 18 or 20.

Further provided is a method for diagnosing the presence of breast cancer by analyzing for changes in levels of BCSG in cells, tissues or bodily fluids compared with levels of BCSG in preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein a change in levels of BCSG in the patient versus the normal human control is associated with breast cancer.

Further provided is a method of diagnosing metastatic breast cancer in a patient having breast cancer which is not known to have metastasized by identifying a human patient suspected of having breast cancer that has metastasized; analyzing a sample of cells, tissues, or bodily fluid from such patient for BCSG; comparing the BCSG levels in such cells, tissues, or bodily fluid with levels of BCSG in preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein an increase in BCSG levels in the patient versus the normal human control is associated with breast cancer which has metastasized.

Also provided by the invention is a method of staging breast cancer in a human by identifying a human patient having breast cancer; analyzing a sample of cells, tissues, or bodily fluid from such patient for BCSG; comparing BCSG levels in such cells, tissues, or bodily fluid with levels of BCSG in

preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein an increase in BCSG levels in the patient versus the normal human control is associated with a cancer which is progressing and a decrease in the levels of BCSG is associated with a cancer which is regressing or in remission.

Further provided is a method of monitoring breast cancer in a human patient for the onset of metastasis. The method comprises identifying a human patient having breast cancer that is not known to have metastasized; periodically analyzing cells, tissues, or bodily fluid from such patient for BCSG; comparing the BCSG levels in such cells, tissue, or bodily fluid with levels of BCSG in preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein an increase in BCSG levels in the patient versus the normal human control is associated with a cancer which has metastasized.

Further provided is a method of monitoring the change in stage of cancer in a human patient having breast cancer by looking at levels of BCSG in the human patient. The method comprises identifying a human patient having breast cancer; periodically analyzing cells, tissues, or bodily fluid from such patient for BCSG; comparing the BCSG levels in such cells, tissue, or bodily fluid with levels of BCSG in preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein an increase in BCSG levels in the patient versus the normal human control is associated with breast cancer which is progressing and a decrease in the levels of BCSG is associated with breast cancer which is regressing or in remission.

Further provided are methods of designing new therapeutic agents targeted to BCSGs for use in imaging and treating cancer. For example, in one embodiment, therapeutic agents such as antibodies targeted against a BCSG or fragments of such antibodies can be used to treat, detect or image

localization of a BCSG in a patient for the purpose of detecting or diagnosing a disease or condition. In this embodiment, an increase in the amount of labeled antibody detected as compared to normal tissue would be indicative of tumor metastases or growth. Such antibodies can be polyclonal, monoclonal, or omniclonal or prepared by molecular biology techniques. The term "antibody", as used herein and throughout the instant specification is also meant to include aptamers and single-stranded oligonucleotides such as those derived from an *in vitro* evolution protocol referred to as SELEX and well known to those skilled in the art. Antibodies can be labeled with a variety of detectable labels including, but not limited to, radioisotopes and paramagnetic metals. Therapeutics agents such as small molecule and antibodies or fragments thereof which decrease the concentration and/or activity of a BCSG can also be used in the treatment of diseases characterized by overexpression of BCSG. In these applications, the antibody can be used without or with derivatization to a cytotoxic agent such as a radioisotope, enzyme, toxin, drug or a prodrug.

Other objects, features, advantages and aspects of the present invention will become apparent to those of skill in the art from the following description. It should be understood, however, that the following description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only. Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following description and from reading the other parts of the present disclosure.

DESCRIPTION OF THE INVENTION

The present invention relates to diagnostic assays and methods, both quantitative and qualitative for detecting, diagnosing, monitoring, staging, prognosticating, *in vivo*

imaging and treating breast cancer by comparing levels of breast cancer specific genes (BCSGs) with levels of BCSGs in a normal human control. BCSG refers, among other things, to native proteins expressed by the genes comprising the polynucleotide sequences of BCSG-1 or Gene ID 332369 (SEQ ID NO: 1), BCSG-2 or Gene ID 480489 (SEQ ID NO:2 or 18), BCSG-3 or Gene ID 274731 (SEQ ID NO:3 or 20), BCSG-4 or Gene ID 173388 (SEQ ID NO:4) or BCSG-5 or Clone ID 3040232, Gene ID 411152 (SEQ ID NO:5). Exemplary proteins expressed by genes BCSG-2 and BCSG-3 are depicted herein as SEQ ID NO:19 and SEQ ID NO:21. The genes encoding these proteins (SEQ ID NO:18 and 20) as well as the proteins (SEQ ID NO:19 and 21) have been disclosed in GenBank as Accession No. AF016492.1 (SEQ ID NO:18), AAC27891.1 (SEQ ID NO:19), AF183819 (SEQ ID NO:20) and AAF23614.1 (SEQ ID NO:21). By "BCSG" it is also meant herein variant polynucleotides which, due to degeneracy in genetic coding, comprise variations in nucleotide sequence as compared to SEQ ID NO: 1, 2, 3, 4, 5, 18 or 20 but which still encode the same proteins. The native protein being detected may be whole, a breakdown product, a complex of molecules or chemically modified. In the alternative, what is meant by BCSG as used herein, means the native mRNAs encoded by the genes comprising BCSG-1 or Gene ID 332369 (SEQ ID NO: 1), BCSG-2 or Gene ID 480489 (SEQ ID NO:2 or 18), BCSG-3 or Gene ID 274731 (SEQ ID NO:3 or 20), BCSG-4 or Gene ID 173388 (SEQ ID NO:4) or BCSG-5 or Clone ID 3040232, Gene ID 411152 (SEQ ID NO:5) or it can refer to the actual genes comprising BCSG-1 or Gene ID 332369 (SEQ ID NO: 1), BCSG-2 or Gene ID 480489 (SEQ ID NO:2 or 18), BCSG-3 or Gene ID 274731 (SEQ ID NO:3 or 20), BCSG-4 or Gene ID 173388 (SEQ ID NO:4) or BCSG-5 or Clone ID 3040232, Gene ID 411152 (SEQ ID NO:5) or levels of polynucleotides which are capable of hybridizing under stringent conditions to the antisense sequences of SEQ ID NO: 1, 2, 3, 4, 5, 18 or 20. Such levels are preferably measured in at least one of, cells, tissues and/or bodily fluids,

including determination of normal and abnormal levels. Thus, for instance, a diagnostic assay in accordance with the invention for diagnosing over-expression of a BCSG protein compared to normal control bodily fluids, cells, or tissue samples can be used to diagnose the presence of cancers, and in particular breast cancer. BCSGs may be measured alone in the methods of the invention, or, more preferably, in combination with other diagnostic markers for breast cancer including other BCSGs as described herein. Other breast cancer markers, in addition to BCSGs, useful in the present invention are known to those of skill in the art.

Diagnostic Assays

The present invention provides methods for diagnosing the presence of cancer, and in particular breast cancer, by analyzing for changes in levels of BCSG in cells, tissues or bodily fluids from a human patient compared with levels of BCSG in cells, tissues or bodily fluids of preferably the same type from a normal human control, wherein an increase in levels of BCSG in the patient versus the normal human control is associated with the presence of cancer.

Without limiting the instant invention, typically, for a quantitative diagnostic assay a positive result indicating the patient being tested has breast cancer is one in which cells, tissues, or bodily fluid levels of a cancer marker, such as BCSG, are at least two times higher, and most preferably are at least five times higher, than in preferably the same cells, tissues, or bodily fluid of a normal human control.

The present invention also provides a method of diagnosing metastatic cancer, and in particular metastatic breast cancer, in a patient having breast cancer which has not yet metastasized. In the method of the present invention, a human cancer patient suspected of having breast cancer which may have metastasized (but which was not previously known to

have metastasized) is identified. This is accomplished by a variety of means known to those of skill in the art.

In the present invention, determining the presence of BCSG in cells, tissues, or bodily fluid, is particularly useful for discriminating between cancers which have not metastasized and cancers which have metastasized. Existing techniques have difficulty discriminating between breast cancer which has metastasized and breast cancer which has not metastasized. However, proper treatment selection is often dependent upon such knowledge.

In the present invention, one of the cancer marker levels measured in cells, tissues, or bodily fluid of a human patient is BCSG. Levels in the human patient are compared with levels of BCSG in preferably the same cells, tissue, or bodily fluid type of a normal human control. That is, if the cancer marker being observed is BCSG in serum, this level is preferably compared with the level of BCSG in serum of a normal human control. An increase in BCSG in the human patient versus the normal human control is associated with a cancer which has metastasized.

Without limiting the instant invention, typically, for a quantitative diagnostic assay a positive result indicating the cancer in the patient being tested or monitored has metastasized is one in which cells, tissues, or bodily fluid levels of a cancer marker, such as BCSG, are at least two times higher, and more preferably are at least five times higher, than in preferably the same cells, tissues, or bodily fluid of a normal human control.

Normal human control as used herein includes a human patient without cancer and/or non cancerous samples from the patient; in the methods for diagnosing metastasis or monitoring for metastasis, normal human control preferably includes samples from a human patient that is determined by reliable methods to have breast cancer which has not

metastasized, such as samples from the same patient prior to metastasis.

Staging

The invention also provides a method of staging cancers in a human patient.

The method comprises identifying a human patient having breast cancer and analyzing a sample of cells, tissues, or bodily fluid from such patient for BCSG. The measured BCSG levels are then compared to levels of BCSG in preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein an increase in BCSG levels in the human patient versus the normal human control is associated with breast cancer which is progressing and a decrease in the levels of BCSG is associated with breast cancer which is regressing or in remission.

Monitoring

Further provided is a method of monitoring breast cancer in a human patient for the onset of metastasis. The method comprises identifying a human patient having breast cancer that is not known to have metastasized; periodically analyzing cells, tissues, or bodily fluid from such patient for BCSG; and comparing the BCSG levels in such cells, tissue, or bodily fluid with levels of BCSG in preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein an increase in BCSG levels in the patient versus the normal human control is associated with breast cancer which has metastasized.

Further provided by this invention is a method of monitoring the change in stage of breast cancer. The method comprises identifying a human patient having breast cancer; periodically analyzing cells, tissues, or bodily fluid from such patient for BCSG; and comparing the BCSG levels in such cells, tissue, or bodily fluid with levels of BCSG in preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein an increase in BCSG levels in

the patient versus the normal human control is associated with breast cancer which is progressing in stage and a decrease in the levels of BCSG is associated with breast cancer which is regressing in stage or in remission.

Monitoring such patients for onset of metastasis is periodic and preferably done on a quarterly basis. However, this may be performed more or less frequently depending on the cancer, the particular patient, and the stage of the cancer.

Prognostic Testing and Clinical Trial Monitoring

The methods described herein can further be utilized as prognostic assays to identify subjects having or at risk of developing a disease or disorder associated with increased levels of BCSG. The present invention provides a method in which a test sample is obtained from a human patient and BCSG is detected. The presence of higher BCSG levels as compared to normal human controls is diagnostic for the human patient being at risk for developing cancer, particularly breast cancer.

The effectiveness of therapeutic agents to decrease expression or activity of the BCSGs of the invention can also be monitored by analyzing levels of expression of the BCSGs in a human patient in clinical trials or in *in vitro* screening assays such as in human cells. In this way, the gene expression pattern can serve as a marker, indicative of the physiological response of the human patient, or cells as the case may be, to the agent being tested.

Detection of genetic lesions or mutations

The methods of the present invention can also be used to detect genetic lesions or mutations in BCSG, thereby determining if a human with the genetic lesion is at risk for breast cancer or has breast cancer. Genetic lesions can be detected, for example, by ascertaining the existence of a deletion and/or addition and/or substitution of one or more nucleotides from the BCSGs of this invention, a chromosomal rearrangement of BCSG, aberrant modification of BCSG (such as

of the methylation pattern of the genomic DNA), the presence of a non-wild type splicing pattern of a mRNA transcript of BCSG, allelic loss of BCSG, and/or inappropriate post-translational modification of BCSG protein. Methods to detect such lesions in the BCSG of this invention are known to those of skill in the art.

Assay Techniques

Assay techniques that can be used to determine levels of gene expression, such as BCSG of the present invention, in a sample derived from a human are well-known to those of skill in the art. Such assay methods include radioimmunoassays, reverse transcriptase PCR (RT-PCR) assays, immunohistochemistry assays, *in situ* hybridization assays, competitive-binding assays, Western Blot analyses, ELISA assays and proteomic approaches, two-dimensional gel electrophoresis (2D electrophoresis) and non-gel based approaches such as mass spectrometry or protein interaction profiling. Among these, ELISAs are frequently preferred to diagnose a gene's expressed protein in biological fluids.

An ELISA assay initially comprises preparing an antibody, if not readily available from a commercial source, specific to BCSG, preferably a monoclonal antibody. In addition a reporter antibody generally is prepared which binds specifically to BCSG. The reporter antibody is attached to a detectable reagent such as a radioactive, fluorescent or enzymatic reagent, for example horseradish peroxidase enzyme or alkaline phosphatase.

To carry out the ELISA, antibody specific to BCSG is incubated on a solid support, e.g., a polystyrene dish, that binds the antibody. Any free protein binding sites on the dish are then covered by incubating with a non-specific protein such as bovine serum albumin. Next, the sample to be analyzed is incubated in the dish, during which time BCSG binds to the specific antibody attached to the polystyrene dish. Unbound sample is washed out with buffer. A reporter

antibody specifically directed to BCSG and linked to a detectable reagent such as horseradish peroxidase is placed in the dish resulting in binding of the reporter antibody to any monoclonal antibody bound to BCSG. Unattached reporter antibody is then washed out. Reagents for peroxidase activity, including a colorimetric substrate are then added to the dish. Immobilized peroxidase, linked to BCSG antibodies, produces a colored reaction product. The amount of color developed in a given time period is proportional to the amount of BCSG protein present in the sample. Quantitative results typically are obtained by reference to a standard curve.

A competition assay can also be employed wherein antibodies specific to BCSG are attached to a solid support and labeled BCSG and a sample derived from the patient or human control are passed over the solid support. The amount of label detected which is attached to the solid support can be correlated to a quantity of BCSG in the sample.

Using all or a portion of a nucleic acid sequence of a BCSG of the present invention as a hybridization probe, nucleic acid methods can also be used to detect BCSG mRNA as a marker for cancer, and in particular breast cancer. Polymerase chain reaction (PCR) and other nucleic acid methods, such as ligase chain reaction (LCR) and nucleic acid sequence based amplification (NASABA), can be used to detect malignant cells for diagnosis and monitoring of various malignancies. For example, reverse-transcriptase PCR (RT-PCR) is a powerful technique which can be used to detect the presence of a specific mRNA population in a complex mixture of thousands of other mRNA species. In RT-PCR, an mRNA species is first reverse transcribed to complementary DNA (cDNA) with use of the enzyme reverse transcriptase; the cDNA is then amplified as in a standard PCR reaction. RT-PCR can thus reveal by amplification the presence of a single species of mRNA. Accordingly, if the mRNA is highly specific for the

cell that produces it, RT-PCR can be used to identify the presence of a specific type of cell.

Hybridization to clones or oligonucleotides arrayed on a solid support (i.e., gridding) can be used to both detect the expression of and quantitate the level of expression of that gene. In this approach, a cDNA encoding a BCSG gene is fixed to a substrate. The substrate may be of any suitable type including but not limited to glass, nitrocellulose, nylon or plastic. At least a portion of the DNA encoding the BCSG gene is attached to the substrate and then incubated with the analyte, which may be RNA or a complementary DNA (cDNA) copy of the RNA, isolated from the tissue of interest. Hybridization between the substrate bound DNA and the analyte can be detected and quantitated by several means including but not limited to radioactive labeling or fluorescence labeling of the analyte or a secondary molecule designed to detect the hybrid. Quantitation of the level of gene expression can be done by comparison of the intensity of the signal from the analyte compared with that determined from known standards. The standards can be obtained by *in vitro* transcription of the target gene, quantitating the yield, and then using that material to generate a standard curve.

Of the proteomic approaches, 2D electrophoresis is a technique well known to those in the art. Isolation of individual proteins from a sample such as serum is accomplished using sequential separation of proteins by different characteristics usually on polyacrylamide gels. First, proteins are separated by size using an electric current. The current acts uniformly on all proteins, so smaller proteins move farther on the gel than larger proteins. The second dimension applies a current perpendicular to the first and separates proteins not on the basis of size but on the specific electric charge carried by each protein. Since no two proteins with different sequences are identical on the basis of both size and charge, the result of a 2D separation

is a square gel in which each protein occupies a unique spot. Analysis of the spots with chemical or antibody probes, or subsequent protein microsequencing can reveal the relative abundance of a given protein and the identity of the proteins in the sample.

The above tests can be carried out on samples derived from a variety cells, bodily fluids and/or tissue extracts (homogenates or solubilized tissue) obtained from the patient including tissue biopsy and autopsy material. Bodily fluids useful in the present invention include blood, urine, saliva, or any other bodily secretion or derivative thereof. Blood can include whole blood, plasma, serum, or any derivative of blood.

In Vivo Targeting of BCSGs/Breast Cancer Therapy

Identification of BCSGs is also useful in the rational design of new therapeutics for imaging and treating cancers, and in particular breast cancer. For example, in one embodiment, antibodies which specifically bind to BCSGs can be raised and used *in vivo* in patients suspected of suffering from cancer. Antibodies which specifically bind a BCSG can be injected into a patient suspected of having cancer for diagnostic and/or therapeutic purposes. The preparation and use of antibodies for *in vivo* diagnosis is well known in the art. For example, antibody-chelators labeled with Indium-111 have been described for use in the radioimmunoscintographic imaging of carcinoembryonic antigen expressing tumors (Sumerdon et al. Nucl. Med. Biol. 1990 17:247-254). In particular, these antibody-chelators have been used in detecting tumors in patients suspected of having recurrent colorectal cancer (Griffin et al. J. Clin. Onc. 1991 9:631-640). Antibodies with paramagnetic ions as labels for use in magnetic resonance imaging have also been described (Lauffer, R.B. Magnetic Resonance in Medicine 1991 22:339-342). Antibodies directed against BCSGs can be used in a similar manner. Labeled antibodies which specifically bind a BCSG can

be injected into patients suspected of having breast cancer for the purpose of diagnosing or staging of the disease status of the patient. The label used will be selected in accordance with the imaging modality to be used. For example, radioactive labels such as Indium-111, Technetium-99m or Iodine-131 can be used for planar scans or single photon emission computed tomography (SPECT). Positron emitting labels such as Fluorine-19 can be used in positron emission tomography. Paramagnetic ions such as Gadlinium (III) or Manganese (II) can be used in magnetic resonance imaging (MRI). Localization of the label permits determination of the spread of the cancer. The amount of label within an organ or tissue also allows determination of the presence or absence of cancer in that organ or tissue.

For patients diagnosed with cancer, and in particular breast cancer, injection of an antibody which specifically binds a BCSG can also have a therapeutic benefit. The antibody may exert its therapeutic effect alone. Alternatively, the antibody can be conjugated to a cytotoxic agent such as a drug, toxin or radionuclide to enhance its therapeutic effect. Drug monoclonal antibodies have been described in the art for example by Garnett and Baldwin, Cancer Research 1986 46:2407-2412. The use of toxins conjugated to monoclonal antibodies for the therapy of various cancers has also been described by Pastan et al. Cell 1986 47:641-648. Yttrium-90 labeled monoclonal antibodies have been described for maximization of dose delivered to the tumor while limiting toxicity to normal tissues (Goodwin and Meares Cancer Supplement 1997 80:2675-2680). Other cytotoxic radionuclides including, but not limited to Copper-67, Iodine-131 and Rhenium-186 can also be used for labeling of antibodies against BCSG.

Antibodies which can be used in these *in vivo* methods include polyclonal, monoclonal and omniclonal antibodies and antibodies prepared via molecular biology techniques.

Antibody fragments and aptamers and single-stranded oligonucleotides such as those derived from an *in vitro* evolution protocol referred to as SELEX and well known to those skilled in the art can also be used.

Screening Assays

The present invention also provides methods for identifying modulators which bind to BCSG protein or have a modulatory effect on the expression or activity of BCSG protein. Modulators which decrease the expression or activity of BCSG protein are believed to be useful in treating breast cancer. Such screening assays are known to those of skill in the art and include, without limitation, cell-based assays and cell free assays.

Small molecules predicted via computer imaging to specifically bind to regions of BCSG can also be designed, synthesized and tested for use in the imaging and treatment of breast cancer. Further, libraries of molecules can be screened for potential anticancer agents by assessing the ability of the molecule to bind to the BCSGs identified herein. Molecules identified in the library as being capable of binding to BCSG are key candidates for further evaluation for use in the treatment of breast cancer. In a preferred embodiment, these molecules will downregulate expression and/or activity of BCSG in cells.

Adoptive Immunotherapy and Vaccines

Adoptive immunotherapy of cancer refers to a therapeutic approach in which immune cells with an antitumor reactivity are administered to a tumor-bearing host, with the aim that the cells mediate either directly or indirectly, the regression of an established tumor. Transfusion of lymphocytes, particularly T lymphocytes, falls into this category and investigators at the National Cancer Institute (NCI) have used autologous reinfusion of peripheral blood lymphocytes or tumor-infiltrating lymphocytes (TIL), T cell cultures from biopsies of subcutaneous lymph nodules, to treat

several human cancers (Rosenberg, S. A., U.S. Patent No. 4,690,914, issued Sep. 1, 1987; Rosenberg, S. A., et al., 1988, N. England J. Med. 319:1676-1680).

The present invention relates to compositions and methods of adoptive immunotherapy for the prevention and/or treatment of primary and metastatic breast cancer in humans using macrophages sensitized to the antigenic BCSG molecules, with or without non-covalent complexes of heat shock protein (hsp). Antigenicity or immunogenicity of the BCSG is readily confirmed by the ability of the BCSG protein or a fragment thereof to raise antibodies or educate naive effector cells, which in turn lyse target cells expressing the antigen (or epitope).

Cancer cells are, by definition, abnormal and contain proteins which should be recognized by the immune system as foreign since they are not present in normal tissues. However, the immune system often seems to ignore this abnormality and fails to attack tumors. The foreign BCSG proteins that are produced by the cancer cells can be used to reveal their presence. The BCSG is broken into short fragments, called tumor antigens, which are displayed on the surface of the cell. These tumor antigens are held or presented on the cell surface by molecules called MHC, of which there are two types: class I and II. Tumor antigens in association with MHC class I molecules are recognized by cytotoxic T cells while antigen-MHC class II complexes are recognized by a second subset of T cells called helper cells. These cells secrete cytokines which slow or stop tumor growth and help another type of white blood cell, B cells, to make antibodies against the tumor cells.

In adoptive immunotherapy, T cells or other antigen presenting cells (APCs) are stimulated outside the body (*ex vivo*), using the tumor specific BCSG antigen. The stimulated cells are then reinfused into the patient where they attack the cancerous cells. Research has shown that using both

cytotoxic and helper T cells is far more effective than using either subset alone. Additionally, the BCSG antigen may be complexed with heat shock proteins to stimulate the APCs as described in U.S. Patent No. 5,985,270.

The APCs can be selected from among those antigen presenting cells known in the art including, but not limited to, macrophages, dendritic cells, B lymphocytes, and a combination thereof, and are preferably macrophages. In a preferred use, wherein cells are autologous to the individual, autologous immune cells such as lymphocytes, macrophages or other APCs are used to circumvent the issue of whom to select as the donor of the immune cells for adoptive transfer. Another problem circumvented by use of autologous immune cells is graft versus host disease which can be fatal if unsuccessfully treated.

In adoptive immunotherapy with gene therapy, DNA of the BCSG can be introduced into effector cells similarly as in conventional gene therapy. This can enhance the cytotoxicity of the effector cells to tumor cells as they have been manipulated to produce the antigenic protein resulting in improvement of the adoptive immunotherapy.

BCSG antigens of this invention are also useful as components of breast cancer vaccines. The vaccine comprises an immunogenically stimulatory amount of an BCSG antigen. Immunogenically stimulatory amount refers to that amount of antigen that is able to invoke the desired immune response in the recipient for the amelioration, or treatment of breast cancer. Effective amounts may be determined empirically by standard procedures well known to those skilled in the art.

The BCSG antigen may be provided in any one of a number of vaccine formulations which are designed to induce the desired type of immune response, e.g., antibody and/or cell mediated. Such formulations are known in the art and include, but are not limited to, formulations such as those described in U.S. Patent 5,585,103. Vaccine formulations of the present

invention used to stimulate immune responses can also include pharmaceutically acceptable adjuvants.

EXAMPLES

The present invention is further described by the following examples. These examples are provided solely to illustrate the invention by reference to specific embodiments. These exemplifications, while illustrating certain specific aspects of the invention, do not portray the limitations or circumscribe the scope of the disclosed invention.

Example 1: Identification of BCSGs via CLASP

Identification of BCSGs (Breast Cancer Specific Genes) was carried out by a systematic analysis of data in the LIFESEQ Gold (LSGold) database available from Incyte Pharmaceuticals, Palo Alto, CA using the data mining Cancer Leads Automatic Search Package (CLASP) developed by diaDexus LLC, Santa Clara CA.

The CLASP performs the following steps:

(1) Selection of highly expressed organ specific genes based on the abundance level of the corresponding EST in the targeted organ versus all the other organs.

(2) Analysis of the expression level of each highly expressed organ specific gene in normal, tumor tissue, disease tissue and tissue libraries associated with tumor or disease.

(3) Selection of the candidates wherein component ESTs are exclusively or more frequently found in tumor libraries.

The CLASP allows the identification of highly expressed organ and cancer specific genes. A final manual in depth evaluation is then performed to finalize the Organ Cancer Specific Genes (OCSGs) selection. Table 1 provides the BCSGs of the present invention identified using CLASP.

Table 1: BCSGs

BCSG	SEQ ID NO:	LSGold Clone ID	LSGold Gene ID
BCSG-1	1	none	332369
BCSG-2	2 or 18	none	480489
BCSG-3	3 or 20	none	274731
BCSG-4	4	none	173388
BCSG-5	5	3040232	411152

Example 2: Determination of mRNA expression of BCSG-5

The mRNA expression level of BCSG, BCSG-5 (SEQ ID NO:5, Clone ID 3040232, Gene ID 411152), also referred to as MAM009, in different tissues was analyzed using Real-Time quantitative PCR. The results presented here for BCSG-5 support the usage of CLASP as a tool for identifying cancer diagnostic markers.

These experiments were carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in detail. Routine molecular biology techniques were carried out as described in standard laboratory manuals, such as Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989).

Real-Time quantitative PCR with fluorescent Taqman probes is a quantitation detection system utilizing the 5'- 3' nuclease activity of Taq DNA polymerase. The method uses an internal fluorescent oligonucleotide probe (Taqman) labeled with a 5' reporter dye and a downstream, 3' quencher dye. During PCR, the 5'-3' nuclease activity of Taq DNA polymerase releases the reporter, whose fluorescence can then be detected by the laser detector of the Model 7700 Sequence Detection System (PE Applied Biosystems, Foster City, CA, USA).

Amplification of an endogenous control is used to standardize the amount of sample RNA added to the reaction and normalize for Reverse Transcriptase (RT) efficiency. Either

cyclophilin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or 18S ribosomal RNA (rRNA) was used as this endogenous control. To calculate relative quantitation between all the samples studied, the target RNA levels for one sample were used as the basis for comparative results (calibrator). Quantitation relative to the "calibrator" can be obtained using the standard curve method or the comparative method (User Bulletin #2: ABI PRISM 7700 Sequence Detection System).

The tissue distribution, and the level of the target gene were determined for every sample in normal and cancer tissue. Total RNA was extracted from normal tissues, cancer tissues, and from cancers and the corresponding matched adjacent tissues. Subsequently, first strand cDNA was prepared with reverse transcriptase and the polymerase chain reaction was done using primers and Taqman probe specific to each target gene. The results were analyzed using the ABI PRISM 7700 Sequence Detector. The absolute numbers are relative levels of expression of the target gene in a particular tissue compared to the calibrator tissue.

Primers used for expression analysis include:

BCSG-5 forward:

ACCCCATTTAGCCTGCCAT (SEQ ID NO:6)

BCSG-5 reverse:

ATGGGAGTATCTCATCTGCTCTCA (SEQ ID NO:7)

Q-PCR probe:

TGTTTGTTCATTCTTCAATTCCAAGGCTTT (SEQ ID NO:8)

The absolute numbers depicted in Table 2 are relative levels of expression of BCSG-5 in 12 normal different tissues. All the values are compared to normal testis (calibrator). These RNA samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals.

Table 2: Relative Levels of BCSG-5 Expression in Pooled Samples

Tissue	NORMAL
Brain	0.00
Heart	0.00
Kidney	0.00
Liver	0.00
Lung	0.00
Mammary gland	106.15
Muscle	0.00
Prostate	0.00
Small Intestine	0.00
Testis	1.00
Thymus	0.00
Uterus	0.00

The relative levels of expression in Table 2 show that BCSG-5 mRNA expression is detected in the pool of normal mammary gland and in testis but not in the other 10 normal tissue pools analyzed. The level of expression in mammary gland is more than 100 fold higher than in testis. These results demonstrate that BCSG-5 mRNA expression is highly specific for mammary gland tissue and is also found in testis. Expression in a male specific tissue is not relevant in detecting cancer in female specific tissues.

The absolute numbers in Table 2 were obtained analyzing pools of samples of a particular tissue from different individuals. They can not be compared to the absolute numbers originated from RNA obtained from tissue samples of a single individual in Table 3.

The absolute numbers depicted in Table 3 are relative levels of expression of BCSG-5 in 78 pairs of matching samples. All the values are compared to normal testis (calibrator). A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual. In addition, 2 unmatched cancer samples (from ovary) and 2 unmatched normal samples (from ovary) were also tested.

Table 3: Relative Levels of BCSG-5 Expression in Individual Samples

Sample ID	Tissue	Cancer	Matching Normal Adjacent	Normal
MamS621	Mammary Gland 1	60.37	0.00	
MamS516	Mammary Gland 2	1.97	1.09	
MamS079	Mammary Gland 3	2.31	2.74	
Mam517	Mammary Gland 4	3.42	2.71	
Mam59X	Mammary Gland 5	0.47	9.56	
MamS127	Mammary Gland 6	0.00	2.22	
MamB011X	Mammary Gland 7	2.52	25.28	
Mam522	Mammary Gland 8	109.66	2.67	
Mam51DN	Mammary Gland 9	11.71	169.77	
Mam19DN	Mammary Gland 10	369.64	28.24	
MamS123	Mammary Gland 11	0.10	1.21	
MamS997	Mammary Gland 12	8.80	2.29	
Mam162X	Mammary Gland 13	7.67	1.08	
Mam220	Mammary Gland 14	11.50	53.60	
Mam699F	Mammary Gland 15	0.52	3.48	
Mam42DN	Mammary Gland 16	1.39	3.54	
Mam76DN	Mammary Gland 17	300.03	84.71	
MamS854	Mammary Gland 18	2.77	2.64	
MamS967	Mammary Gland 19	892.68	4.46	
Mam986	Mammary Gland 20	14.40	19.27	
MamS699	Mammary Gland 21	2.24	1.43	
Mam355	Mammary Gland 22	223.37	0.00	
MamA06X	Mammary Gland 23	1220.50	2.26	
MamS570	Mammary Gland 24	0.00	120.39	
MamS918	Mammary Gland 25	181.43	60.30	
End12XA	Endometrium 1	0.00	0.00	

End28XA	Endometrium 2	0.00	0.00	
End3AX	Endometrium 3	0.00	0.00	
End4XA	Endometrium 4	0.00	0.00	
End5XA	Endometrium 5	0.00	0.00	
End10479	Endometrium 6	0.00	0.00	
End65RA	Endometrium 7	0.00	0.00	
End68X	Endometrium 8	0.00	0.00	
CvxNKS18	Cervix 1	0.00	0.00	
CvxNKS54	Cervix 2	0.00	0.00	
CvxNK23	Cervix 3	0.00	0.00	
CvxNK24	Cervix 4	0.00	0.00	
CvxKS52	Cervix 5	0.00	0.00	
CvxKS83	Cervix 6	0.00	0.00	
Utr141XO	Uterus 1	0.00	0.00	
Utr135XO	Uterus 2	0.00	0.00	
Utr23XU	Uterus 3	0.00	0.00	
Utr85XU	Uterus 4	0.00	0.00	
LngC20X	Lung 1	0.00	0.00	
LngSQ56	Lung 2	0.00	0.00	
Lng90X	Lung 3	0.00	0.00	
LngAC11	Lung 4	0.00	0.00	
Pro101XB	Prostate 1	0.00	0.00	
Pro23B	Prostate 2	0.00	0.00	
Skn448S	Skin 1	0.00	0.00	
Skn784S	Skin 2	0.00	0.00	
ClnSG45	Colon 1	0.00	0.00	
ClnTX01	Colon 2	0.00	0.00	
ClnAS46	Colon 3	0.00	0.00	
ClnAS67	Colon 4	0.00	0.00	
BldTR17	Bladder 1	0.00	0.00	

Bld66X	Bladder 2	0.00	0.00	
Kid11XD	Kidney 1	0.00	0.00	
Kid5XD	Kidney 2	0.00	0.00	
Kid109XD	Kidney 3	0.00	0.00	
Liv532L	Liver 1	0.00	0.00	
Liv175L	Liver 2	0.00	0.00	
Liv187L	Liver 3	0.00	0.00	
OvrG010	Ovary 1	0.00	0.00	
Ovr1005O	Ovary 2	0.00		
Ovr1028	Ovary 3	0.00		
Ovr103X	Ovary 4	0.00	0.00	
Ovr18GA	Ovary 5			0.00
Ovr206I	Ovary 6			0.00
Pan92X	Pancreas 1	0.00	0.00	
PanC044	Pancreas 2	0.00	0.00	
SmIH89	Small Intestine 1	0.00	0.00	
SmI21XA	Small Intestine 2	0.00	0.00	
Sto15S	Stomach 1	0.00	0.00	
StoAC44	Stomach 2	0.00	0.00	
Sto288S	Stomach 3	0.00	0.00	
Sto531S	Stomach 4	0.00	0.00	
Thr644T	Thyroid 1	0.00	0.00	
Thr145T	Thyroid 2	0.00	0.00	
Thr939T	Thyroid 3	0.00	0.00	
Tst39X	Testis 1	0.00	0.00	
Tst663T	Testis 2	0.00	0.00	

0.00= Negative

Among 160 samples in Table 3 representing 17 different tissues significant expression is seen only in mammary gland tissues. These results confirm the tissue specificity results obtained with normal samples shown in Table 2. Table 2 and

Table 3 represent a combined total of 172 samples in 21 human tissue types. One hundred and twenty samples representing 20 different tissue types excluding mammary gland had no detectable level of BCSG-5 mRNA. Other than mammary gland, BCSG-5 is detected only in one tissue type (testis) and then only in the pooled tissue sample (Table 2) but not in the matched testis cancer samples (Table 3; testis 1 and 2).

Comparisons of the level of mRNA expression in breast cancer samples and the normal adjacent tissue from the same individuals are shown in Table 3. BCSG-5 is expressed at higher levels in 12 of 25 (48%) cancer samples (mammary gland 1, 2, 8, 10, 12, 13, 17, 19, 21, 22, 23 and 25) compared to normal adjacent tissue.

Altogether, the high level of tissue specificity, plus the mRNA overexpression in 48% of the mammary gland matching samples tested are indicative of BCSG-5, and more generally BCSGs selected by CLASP, being good diagnostic markers for breast cancer.

Example 3: Determination of mRNA expression of BCSG-1

The mRNA expression level of BCSG, BCSG-1 (SEQ ID NO:1, Gene ID 332369), also referred to as MAM014 were also determined in accordance with methods as set forth in Example 2.

Real-Time quantitative PCR was done using the following primers:

BCSG-1 forward:

5' GCCCATTAGCACCCAGATAAT 3' (SEQ ID NO:9)

BCSG-2 reverse:

5' GCCAACCCTTCACCTAAGAAA 3' (SEQ ID NO:10)

Q-PCR probe

5' CTTCCCACTGTACAAAGATTTTCCAGGATG 3' (SEQ ID NO:11)

The absolute numbers depicted in Table 4 are relative levels of expression of BCSG-1 in 37 normal samples from 25 different tissues. All the values are compared to normal

kidney (calibrator). These RNA samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals; except for the blood samples that they are normal samples from a single individual.

Table 4: Relative Levels of BCSG-1 Expression in Pooled Samples

Tissue	NORMAL
Adrenal Gland	1.09
Bladder	0.05
Brain	24.00
Cervix	3.84
Colon	0.00
Endometrium	10.41
Esophagus	0.18
Heart	0.01
Kidney	1.00
Liver	0.02
Lung	4.35
Mammary	1.19
Muscle	0.09
Ovary	23.51
Pancreas	0.86
Prostate	7.75
Rectum	0.33
Small Intestine	0.85
Spleen	17.51
Stomach	2.42
Testis	111.04
Thymus	9.95
Trachea	6.43
Uterus	0.68
Blood 1	34.42
Blood 2	0.00
Blood 3	21.19
Blood 4	25.19
Blood 5	51.09
Blood 6	1144.10
Blood 7	59.10
Blood 8	60.13
Blood 9	37.53
Blood 10	0.00
Blood 11	15.30
Blood 12	0.00
Blood 13	0.00

The relative levels of expression in Table 4 show that BCSG-1 mRNA expression is detected in the pool of normal mammary gland as well as in the other normal tissue analyzed.

The absolute numbers in Table 5 were obtained analyzing pools of samples of a particular tissue from different individuals, except for the blood samples. They can not be compared to the absolute numbers originated from RNA obtained from tissue samples of a single individual in Table 5.

The absolute numbers depicted in Table 5 are relative levels of expression of BCSG-1 in 77 pairs of matching samples. All the values are compared to normal kidney (calibrator). A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual. In addition, 3 unmatched cancer samples (from ovary) and 3 unmatched normal samples (from ovary) were also tested.

Table 5: Relative Levels of BCSG-1 Expression in Individual Samples

Sample ID	Tissue	Cancer	Matching Normal Adjacent	Normal
MamS621	Mammary Gland 1	7.48	0.00	
MamS516	Mammary Gland 2	0.90	0.00	
Mam173M	Mammary Gland 3	3.96	0.00	
Mam497M	Mammary Gland 4	9.71	0.00	
MamS079	Mammary Gland 5	1.72	0.00	
Mam517	Mammary Gland 6	8.88	3.35	
Mam726M	Mammary Gland 7	3.04	0.00	
Mam59X	Mammary Gland 8	7.01	15.73	
MamS127	Mammary Gland 9	24.59	0.00	
MamB011X	Mammary Gland 10	8.43	1.14	
MamS22	Mammary Gland 11	14.55	0.00	
Mam15DN	Mammary Gland 12	4.16	0.00	
Mam51DN	Mammary Gland 13	32.90	3.11	
Mam976M	Mammary Gland 14	6.17	0.00	
Mam543M	Mammary Gland 15	34.42	0.32	

Mam245M	Mammary Gland 16	10.82	0.00	
MamS123	Mammary Gland 17	0.37	0.00	
MamS997	Mammary Gland 18	0.56	0.00	
Mam162X	Mammary Gland 19	6.09	0.52	
Mam220	Mammary Gland 20	2.08	0.58	
Mam699F	Mammary Gland 21	6.75	6.36	
Mam42DN	Mammary Gland 22	10.16	0.00	
Mam76DN	Mammary Gland 23	31.23	4.68	
MamS854	Mammary Gland 24	6.11	0.00	
MamS967	Mammary Gland 25	86.22	0.00	
Mam986	Mammary Gland 26	13.36	9.00	
MamS699	Mammary Gland 27	4.52	0.00	
Mam355	Mammary Gland 28	107.38	0.00	
MamA06X	Mammary Gland 29	43.26	0.00	
MamS570	Mammary Gland 30	68.36	64.22	
MamS918	Mammary Gland 31	2.49	0.86	
Bld66X	Bladder	0.00	3.24	
ClnTX01	Colon 1	0.55	0.00	
ClnAS43	Colon 2	1.11	0.00	
ClnAS49	Colon 3	0.69	0.60	
ClnRS45	Colon 4	0.00	0.00	
CvxNK24	Cervix 1	2.53	0.69	
CvxNKS54	Cervix 2	1.71	0.54	
CvxNK23	Cervix 3	0.34	0.00	
CvxNKS81	Cervix 4	0.00	0.00	
End5XA	Endometrium 1	1.16	2.85	
End8911	Endometrium 2	2.62	1.65	
End8963	Endometrium 3	6.50	0.00	
End28XA	Endometrium 4	1.75	1.33	
End65RA	Endometrium 5	0.45	0.00	

End12XA	Endometrium 6	34.80	3.55	
End3AX	Endometrium 7	0.00	0.00	
Kid11XD	Kidney 1	0.94	1.42	
Kid124D	Kidney 2	1.35	0.00	
Liv532L	Liver 1	0.33	0.00	
Liv390L	Liver 2	0.66	0.00	
LngSQ56	Lung 1	0.00	0.00	
Lng223L	Lung 2	0.20	0.00	
LngLC71	Lung 3	7.67	8.20	
LngAC90	Lung 4	11.70	0.98	
Lng75XC	Lung 5	0.00	0.00	
OvrA082	Ovary 1	21.33	42.96	
OvrA082	Ovary 2	52.68	186.62	
Ovr103X	Ovary 3	44.88	17.67	
Ovr1005O	Ovary 4	6.89		
Ovr1028	Ovary 5	0.44		
Ovr1040O	Ovary 6	0.80		
Ovr18GA	Ovary 7			6.63
Ovr206I	Ovary 8			1.46
Ovr20GA	Ovary 9			5.96
Pan92X	Pancreas 1	0.00	0.00	
Pan77X	Pancreas 2	0.24	0.00	
Pro23B	Prostate 1	0.80	0.00	
Pro13XB	Prostate 2	0.05	17.75	
Skn448S	Skin 1	0.00	0.00	
Skn784S	Skin 2	0.13	0.11	
SmIntH89	Small Intestine 1	0.00	0.00	
Sto264S	Stomach 1	0.80	1.15	
Sto15S	Stomach 2	0.23	2.29	
Sto27S	Stomach 3	1.07	1.35	

Thr644T	Thyroid 1	0.00	0.00	
Thr143T	Thyroid 2	0.58	0.00	
Tst663T	Testis 1	5.46	1.80	
Tst647T	Testis 2	1.27	5.68	
Utr23XU	Uterus 1	9.38	1.17	
Utr85XU	Uterus 2	4.36	2.17	
Utr141XO	Uterus 3	0.00	0.00	
Utr135XO	Uterus 4	7.53	10.10	

0.00= Negative

Table 5 represents 160 samples in 17 different tissues. Table 4 and Table 5 represent a combined total of 197 samples in 27 human tissue types. Comparisons of the level of mRNA expression in breast cancer samples and the normal adjacent tissue from the same individuals are shown in Table 5. BCSG-1 is expressed at higher levels in 27 of 30 (90%) cancer samples (mammary gland 1-7, 9-20, 22-25, 27-29, and 31) compared to normal adjacent tissue.

Example 4: Determination of mRNA expression of BCSG-2

The mRNA expression level of BCSG, BCSG-2 (SEQ ID NO:2 or 18, Gene ID 480489), also referred to as MAM013 were also determined in accordance with methods as set forth in Example 2.

Real-Time quantitative PCR was done using the following primers:

BCSG-2 forward:

5' CCTGGAGTTTTCAATTTCCTCA 3' (SEQ ID NO:12)

BCSG-2 reverse:

5' CCCCAGAGAAAACACCACAA 3' (SEQ ID NO:13)

Q-PCR probe

5' ACTCCTCCATTTCCTTAGGTAGGGGTTTG 3' (SEQ ID NO:14)

The absolute numbers depicted in Table 6 are relative levels of expression of BCSG-2 in 37 normal samples from 25

different tissues. All the values are compared to normal liver (calibrator). These RNA samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals, except for the blood samples that they are normal samples from a single individual.

Table 6: Relative Levels of BCSG-2 Expression in Pooled Samples

Tissue	NORMAL
Adrenal Gland	0.00
Bladder	0.00
Brain	0.00
Cervix	0.00
Colon	0.00
Endometrium	0.33
Esophagus	0.00
Heart	0.02
Kidney	0.28
Liver	1.00
Lung	0.07
Mammary	20.39
Muscle	0.00
Ovary	0.00
Pancreas	0.05
Prostate	0.26
Rectum	0.00
Small Intestine	0.00
Spleen	0.00
Stomach	0.12
Testis	1.55
Thymus	0.55
Trachea	1.23
Uterus	0.00
Blood 1	0.00
Blood 2	0.00
Blood 3	0.00
Blood 4	0.00
Blood 5	6.17
Blood 6	0.00
Blood 7	0.00
Blood 8	0.00
Blood 9	16.97
Blood 10	0.00
Blood 11	77.98
Blood 12	0.00
Blood 13	0.00

The relative levels of expression in Table 6 show that BCSG-2 mRNA expression is detected in the pool of normal mammary gland. The level of expression is higher than in the other tissues with the exception of two blood samples.

The absolute numbers in Table 6 were obtained analyzing pools of samples of a particular tissue from different individuals, except for the blood samples. They can not be compared to the absolute numbers originated from RNA obtained from tissue samples of a single individual in Table 7.

The absolute numbers depicted in Table 7 are relative levels of expression of BCSG-2 in 76 pairs of matching samples. All the values are compared to normal liver (calibrator). A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual. In addition, 3 unmatched cancer samples (from ovary) and 3 unmatched normal samples (from ovary) were also tested.

Table 7: Relative Levels of BCSG-2 Expression in Individual Samples

Sample ID	Tissue	Cancer	Matching Normal Adjacent	Normal
MamS621	Mammary Gland 1	0.00	0.00	
Mam173M	Mammary Gland 2	7.21	0.00	
Mam497M	Mammary Gland 3	1634.92	31.12	
MamS079	Mammary Gland 4	42.56	1.39	
Mam517	Mammary Gland 5	2.42	4.21	
Mam726M	Mammary Gland 6	0.00	6.75	
Mam59X	Mammary Gland 7	0.00	16.11	
MamS127	Mammary Gland 8	5.31	0.00	
MamB011X	Mammary Gland 9	0.87	182.28	

Mam522	Mammary Gland 10	480.47	0.18	
Mam19DN	Mammary Gland 11	4.79	0.22	
Mam51DN	Mammary Gland 12	19.49	72.76	
Mam976M	Mammary Gland 13	62.25	0.00	
Mam543M	Mammary Gland 14	103.97	0.00	
Mam245M	Mammary Gland 15	49.01	615.24	
MamS123	Mammary Gland 16	0.42	1.27	
MamS997	Mammary Gland 17	0.24	0.66	
Mam162X	Mammary Gland 18	0.45	1.39	
Mam220	Mammary Gland 19	0.00	0.00	
Mam699F	Mammary Gland 20	0.00	12.38	
Mam42DN	Mammary Gland 21	44.48	11.47	
Mam76DN	Mammary Gland 22	9.32	26.26	
MamS854	Mammary Gland 23	6.50	103.61	
MamS967	Mammary Gland 24	3.36	5.13	
Mam986	Mammary Gland 25	7.67	65.12	
MamS699	Mammary Gland 26	1.68	11.63	
Mam355	Mammary Gland 27	1.32	0.00	
MamA06X	Mammary Gland 28	1.73	0.26	
MamS570	Mammary Gland 29	0.00	194.69	
MamS918	Mammary Gland 30	0.07	0.13	
Bld66X	Bladder	0.00	0.00	
ClnTX01	Colon 1	0.00	0.00	
ClnAS43	Colon 2	0.00	0.00	
ClnAS49	Colon 3	0.00	0.00	
ClnRS45	Colon 4	0.00	0.01	
CvxNK24	Cervix 1	0.00	0.00	
CvxNKS54	Cervix 2	0.00	0.00	
CvxNK23	Cervix 3	0.02	0.00	
CvxNKS81	Cervix 4	0.00	0.00	

End5XA	Endometrium 1	0.00	0.00	
End8911	Endometrium 2	0.00	0.00	
End8963	Endometrium 3	0.00	0.00	
End28XA	Endometrium 4	0.05	0.00	
End65RA	Endometrium 5	0.00	0.00	
End12XA	Endometrium 6	0.23	0.00	
End3AX	Endometrium 7	0.00	0.05	
Kid11XD	Kidney 1	0.04	0.00	
Kid124D	Kidney 2	0.37	0.00	
Liv532L	Liver 1	0.00	2.02	
Liv390L	Liver 2	0.08	0.56	
Lng223L	Lung 1	0.00	0.00	
LngLC71	Lung 2	0.00	0.00	
LngSQ56	Lung 3	0.00	0.00	
LngAC90	Lung 4	0.00	0.00	
Lng75XC	Lung 5	0.00	0.00	
OvrA082	Ovary 1	0.00	0.00	
OvrA082	Ovary 2	0.00	0.00	
Ovr103X	Ovary 3	0.07	0.00	
Ovr1005O	Ovary 4	1.09		
Ovr1028	Ovary 5	0.00		
Ovr1040O	Ovary 6	0.00		
Ovr18GA	Ovary 7			0.00
Ovr206I	Ovary 8			0.00
Ovr20GA	Ovary 9			0.00
Pan92X	Pancreas 1	0.00	0.00	
Pan77X	Pancreas 2	1.91	1.11	
Pro23B	Prostate 1	0.01	0.00	
Pro13XB	Prostate 2	0.00	0.00	
Skn448S	Skin 1	0.00	0.00	

Skn784S	Skin 2	0.00	0.00	
SmIntH89	Small Intestine 1	0.00	0.02	
Sto264S	Stomach 1	0.00	0.00	
Sto15S	Stomach 2	0.04	0.00	
Sto27S	Stomach 3	0.00	0.00	
Thr644T	Thyroid 1	0.00	0.12	
Thr143T	Thyroid 2	0.03	3.73	
Tst663T	Testis 1	0.09	0.00	
Tst647T	Testis 2	0.55	0.00	
Utr23XU	Uterus 1	0.00	0.00	
Utr85XU	Uterus 2	0.00	2.85	
Utr141XO	Uterus 3	0.04	0.00	
Utr135XO	Uterus 4	0.17	0.12	

0.00= Negative

Table 7 represents 158 samples in 17 different tissues. Table 6 and Table 7 represent a combined total of 195 samples in 25 human tissue types. Comparisons of the level of mRNA expression in breast cancer samples and the normal adjacent tissue from the same individuals are shown in Table 7. BCSG-2 is expressed at higher levels in 11 of 30 (37%) cancer samples (mammary gland 2-4, 8, 10, 11, 13, 14, 21, 27, 28) compared to normal adjacent tissue.

Example 5: Determination of mRNA expression of BCSG-3

The mRNA expression level of BCSG, BCSG-3 (SEQ ID NO:3 or 20, Gene ID 274731), also referred to as MAM017 were also determined in accordance with methods as set forth in Example 2.

Real-Time quantitative PCR was done using the following primers:

BCSG-3 forward:

5' GAGCACTTCCTTTTGGTTTTTC 3' (SEQ ID NO:15)

BCSG-3 reverse:

5' GCCCTAGCATATTCCAGAAGTTC 3' (SEQ ID NO:16)

Q-PCR probe

5' TAGACAGTGGGCTCACATGTTCCTGATAGTG 3' (SEQ ID NO:17)

The absolute numbers depicted in Table 8 are relative levels of expression of BCSG-3 in 36 normal samples from 25 different tissues. All the values are compared to normal prostate (calibrator). These RNA samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals, except for the blood samples that they are normal samples from a single individual.

Table 8: Relative Levels of BCSG-3 Expression in Pooled Samples

Tissue	NORMAL
Adrenal Gland	0.16
Bladder	0.02
Brain	0.12
Cervix	1.41
Colon	0.01
Endometrium	3.77
Esophagus	0.03
Heart	0.02
Kidney	0.07
Liver	0.00
Lung	0.59
Mammary	7.67
Muscle	0.08
Ovary	0.94
Pancreas	0.14
Prostate	1.00
Rectum	0.13
Small Intestine	0.05
Spleen	0.89
Stomach	0.17
Testis	0.20
Thymus	0.56
Trachea	0.39
Uterus	1.22
Blood 1	1.91
Blood 2	1.76
Blood 3	0.76
Blood 4	0.18
Blood 5	1.41
Blood 6	1.54
Blood 7	0.48
Blood 8	1.92
Blood 9	1.63

Blood 10	1.65
Blood 11	1.83
Blood 12	0.37

The relative levels of expression in Table 8 show that BCSG-3 mRNA expression is detected in the pool of normal mammary gland with the highest expression value.

The absolute numbers in Table 8 were obtained analyzing pools of samples of a particular tissue from different individuals, except for the blood samples. They can not be compared to the absolute numbers originated from RNA obtained from tissue samples of a single individual in Table 9.

The absolute numbers depicted in Table 9 are relative levels of expression of BCSG-3 in 68 pairs of matching samples. All the values are compared to normal prostate (calibrator). A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual. In addition, 1 unmatched cancer sample (from ovary) and 1 unmatched normal sample (from ovary) were also tested.

Table 9: Relative Levels of BCSG-3 Expression in Individual Samples

Sample ID	Tissue	Cancer	Matching Normal Adjacent	Normal
Mam497M	Mammary Gland 1	3.22	1.11	
Mam173M	Mammary Gland 2	1.39	17.75	
Mam726M	Mammary Gland 3	7.62	1.31	
MamS516	Mammary Gland 4	11.08	0.10	
MamS621	Mammary Gland 5	18.25	0.05	
MamS079	Mammary Gland 6	0.78	0.24	
Mam19DN	Mammary Gland 7	71.01	1.39	
Mam522	Mammary Gland 8	3.35	0.16	

MamS127	Mammary Gland 9	48.00	0.48	
Mam162X	Mammary Gland 10	0.18	0.65	
MamS123	Mammary Gland 11	49.69	0.00	
MamS997	Mammary Gland 12	141.53	0.48	
Mam543M	Mammary Gland 13	34.66	0.10	
Mam976M	Mammary Gland 14	0.37	0.10	
Mam74DN	Mammary Gland 15	35.14	4.36	
MamS918	Mammary Gland 16	16.74	5.58	
MamS854	Mammary Gland 17	1.11	1.58	
Mam986	Mammary Gland 18	0.58	1.14	
MamS967	Mammary Gland 19	121.94	2.97	
Mam355	Mammary Gland 20	11.35	0.06	
MamA06X	Mammary Gland 21	7.65	0.13	
Bld32XK	Bladder 1	0.17	0.02	
Bld66X	Bladder 2	0.17	0.13	
BldTR17	Bladder 3	6.21	0.00	
Bld46XK	Bladder 4	0.06	0.00	
BldTR14	Bladder 5	0.79	0.19	
ClnB56	Colon 1	0.12	0.10	
ClnDC63	Colon 2	0.21	1.09	
CvxKS52	Cervix 1	10.74	2.21	
CvxNK24	Cervix 2	6.96	4.63	
CvxKS83	Cervix 3	2.29	2.23	
CvxNK23	Cervix 4	0.22	1.54	
End10479	Endometrium 1	4.68	5.13	
End12XA	Endometrium 2	1.68	2.00	
End5XA	Endometrium 3	0.38	0.40	
End65RA	Endometrium 4	0.49	0.38	
End28XA	Endometrium 5	4.32	2.94	
End3AX	Endometrium 6	0.21	0.21	

	Kid6XD	Kidney 1	0.06	0.16	
	Kid710K	Kidney 2	0.03	0.10	
	Liv175L	Liver 1	1.24	0.09	
	Liv187L	Liver 2	0.07	0.06	
	Liv15XA	Liver 3	0.02	0.01	
	Lng47XQ	Lung 1	0.15	0.06	
	LngAC88	Lung 2	1.78	0.95	
	LngAC90	Lung 3	0.46	0.00	
	LngSQ80	Lung 4	1.91	0.35	
	Ovr103X	Ovary 1	25.63	2.52	
	OvrA084	Ovary 2	7.70	3.19	
	OvrG010	Ovary 3	0.62	3.40	
	OvrG021	Ovary 4	0.09	0.45	
	Ovr1118	Ovary 5	0.13		
	Ovr32RA	Ovary 6			2.81
	Pan77X	Pancreas 1	0.56	0.19	
	Pan82XP	Pancreas 2	0.62	0.73	
	Pro109XB	Prostate 1	0.00	0.10	
	Pro125XB	Prostate 2	0.05	0.01	
	Skn248S	Skin 1	0.94	0.02	
	Skn287S	Skin 2	0.36	0.05	
	SmIntH89	Small Intestine 1	0.12	0.04	
	SmInt 21XA	Small Intestine 2	0.29	0.01	
	Sto115S	Stomach 1	1.17	0.44	
	Sto15S	Stomach 2	0.15	0.18	
	StoMT54	Stomach 3	0.12	0.18	
	Thr590D	Thyroid	3.46	3.33	
	Tst647T	Testis	1.06	0.24	
	Utr141XO	Uterus 1	2.86	0.51	
	Utr23XU	Uterus 2	0.60	0.13	

Confidential

Utr85XU	Uterus 3	12.21	1.43	
Utr135XO	Uterus 4	2.98	3.93	

0.00= Negative

Table 9 represents 138 samples in 17 different tissues. Table 8 and Table 9 represent a combined total of 174 samples in 26 human tissue types.

Comparisons of the level of mRNA expression in breast cancer samples and the normal adjacent tissue from the same individuals are shown in Table 8. BSCG-3 is expressed at higher levels in 17 of 21 (81%) cancer samples (mammary gland 1, 3-6, 7-9, 11-16, 19-21) compared to normal adjacent tissue.

Genentech Exhibit 2009

What is claimed is:

1. A BCSG comprising:

(a) a polynucleotide of SEQ ID NO:1, 2, 3, 4, 5, 18 or 20 or a variant thereof;

(b) a protein expressed by a polynucleotide of SEQ ID NO:1, 2, 3, 4, 5, 18 or 20 or a variant thereof; or

(c) a polynucleotide which is capable of hybridizing under stringent conditions to the antisense sequence of SEQ ID NO: 1, 2, 3, 4, 5, 18 or 20.

2. The BCSG of claim 1 comprising a protein of SEQ ID NO:19 or 21.

3. A method for diagnosing the presence of breast cancer in a patient comprising:

(a) determining levels of BCSG in cells, tissues or bodily fluids in a patient; and

(b) comparing the determined levels of BCSG with levels of BCSG in cells, tissues or bodily fluids from a normal human control, wherein a change in determined levels of BCSG in said patient versus normal human control is associated with the presence of breast cancer.

4. A method of diagnosing metastases of breast cancer in a patient comprising:

(a) identifying a patient having breast cancer that is not known to have metastasized;

(b) determining BCSG levels in cells, tissues, or bodily fluid from said patient; and

(c) comparing the determined BCSG levels with levels of BCSG in cells, tissue, or bodily fluid of a normal human control, wherein an increase in determined BCSG levels in the patient versus the normal human control is associated with breast cancer which has metastasized.

5. A method of staging breast cancer in a patient having breast cancer comprising:

(a) identifying a patient having breast cancer;

(b) determining BCSG levels in a sample of cells, tissue, or bodily fluid from said patient; and

(c) comparing determined BCSG levels with levels of BCSG in cells, tissues, or bodily fluid of a normal human control, wherein an increase in determined BCSG levels in said patient versus the normal human control is associated with breast cancer which is progressing and a decrease in the determined BCSG levels is associated with breast cancer which is regressing or in remission.

6. A method of monitoring breast cancer in a patient for the onset of metastasis comprising:

(a) identifying a patient having breast cancer that is not known to have metastasized;

(b) periodically determining levels of BCSG in samples of cells, tissues, or bodily fluid from said patient; and

(c) comparing the periodically determined BCSG levels with levels of BCSG in cells, tissues, or bodily fluid of a normal human control, wherein an increase in any one of the periodically determined BCSG levels in the patient versus the normal human control is associated with breast cancer which has metastasized.

7. A method of monitoring a change in stage of breast cancer in a patient comprising:

(a) identifying a patient having breast cancer;

(b) periodically determining levels of BCSG in cells, tissues, or bodily fluid from said patient; and

(c) comparing the periodically determined BCSG levels with levels of BCSG in cells, tissues, or bodily fluid of a normal human control, wherein an increase in any one of the periodically determined BCSG levels in the patient versus

the normal human control is associated with breast cancer which is progressing in stage and a decrease is associated with breast cancer which is regressing in stage or in remission.

8. A method of identifying potential therapeutic agents for use in imaging and treating breast cancer comprising screening molecules for an ability to bind to BCSG wherein the ability of a molecule to bind to BCSG is indicative of the molecule being useful in imaging and treating breast cancer.

9. An antibody which specifically binds BCSG.

10. The antibody of claim 9 wherein the BCSG comprises SEQ ID NO: 1, 2, 3, 4, 5, 18, 19, 20 or 21.

11. A method of imaging breast cancer in a patient comprising administering to the patient the antibody of claim 9.

12. The method of claim 11 wherein said antibody is labeled with paramagnetic ions or a radioisotope.

13. A method of treating breast cancer in a patient comprising administering to the patient the antibody of claim 9.

14. The method of claim 13 wherein the antibody is conjugated to a cytotoxic agent.

15. A method of treating breast cancer in a patient comprising administering to the patient a molecule which downregulates expression or activity of a BCSG.

16. A method of inducing an immune response against a target cell expressing a BCSG comprising delivering to a human patient an immunogenically stimulatory amount of a BCSG protein so that an immune response is mounted against the target cell.

17. A vaccine for treating breast cancer comprising a BCSG.

DocID: 20020142

ABSTRACT

The present invention provides new markers and methods for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating breast cancer.

Docket No. DEX-0117

Docket No.
DEX-0117

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

A NOVEL METHOD OF DIAGNOSING, MONITORING, STAGING, IMAGING AND TREATING BREAST CANCER

the specification of which

(check one)

☒ is attached hereto.

☐ was filed on _____ as United States Application No. or PCT International Application Number _____

and was amended on _____

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)			Priority Not Claimed
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	☐
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	☐
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	☐

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

60/166,973	November 23, 1999
(Application Serial No.)	(Filing Date)
(Application Serial No.)	(Filing Date)
(Application Serial No.)	(Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. *(list name and registration number)*



26259
PATENT _TRADEMARK OFFICE

Send Correspondence to: **Kathleen A. Tyrrell**
Licata & Tyrrell
66 E. Main Street
Marlton, NJ 08053

Direct Telephone Calls to: *(name and telephone number)*
Kathleen A. Tyrrell, Tel: 856-810-1515

Full name of sole or first inventor
Susana Salceda

Sole or first inventor's signature — Date

Residence
San Jose, CA

Citizenship
Argentina

Post Office Address
4118 Crescendo Avenue

San Jose, CA 95136

Full name of second inventor, if any
Robert Cafferkey

Second inventor's signature — Date

Residence
San Jose, CA

Citizenship
Ireland

Post Office Address
350 Elan Village Lane, Apt. 218

San Jose, CA 95134

Full name of third inventor, if any
Herve Recipon

Third inventor's signature Date

Residence
San Francisco, CA

Citizenship
France

Post Office Address
85 Fortuna Avenue

San Francisco, CA 94115

Full name of fourth inventor, if any
Yongming Sun

Fourth inventor's signature Date

Residence
San Jose, CA

Citizenship
China

Post Office Address
869 S. Winchester Boulevard

San Jose, CA 95128

Full name of fifth inventor, if any

Fifth inventor's signature Date

Residence

Citizenship

Post Office Address

Full name of sixth inventor, if any

Sixth inventor's signature Date

Residence

Citizenship

Post Office Address

SEQUENCE LISTING

<110> Salceda, Susana
Cafferkey, Robert
Recipon, Herve
Sun, Yongming

<120> A NOVEL METHOD OF DIAGNOSING, MONITORING, STAGING, IMAGING AND TREATING BREAST CANCER

<130> DEX-0117

<140>
<141>

<150> 60/166,973
<151> 1999-11-23

<160> 21

<170> PatentIn Ver. 2.0

<210> 1
<211> 1078
<212> DNA
<213> Homo sapiens

<400> 1
ggatgataca agagccaaga agggacattt gagttgtgtc gcttagatag gaaagggatc 60
cagggaaaat caacagtaag tgaggatgag cagcgtctct tggttttcat tgaggataga 120
gtaagagatt gagtttagat tgcaacagaa ggaattagtt tagataccag gaagaacttc 180
ctagcctgaa gatttgtcat agtgtctgct ttctagatat ctgggaaaga tttgataata 240
gttgtttgtg aatagaaagg aggatatgat gtttttattg gccattttgc gggactcttc 300
gacttcttgc tgctgtctct tgaggataca ttccaattcc atcctggcga gatccaagtg 360
cttacgtact gtctccttag ctgccttaga gtaaacgatc atcagttcaa tggaccaaaa 420
tcaccttcag ccatgtggtt tcttcatcat catggatttc ttttggttga caaacattct 480
ggctctcaga tgcaaaaagt cacactggga aatgaactgt aagtggtgaa attagttttg 540
gtatttaatt taaaactaca ttttagtttt tctcttctct tctatgttgc aatgaatgta 600
aagtatttgg gatccagtgc ttataaacct ttccttcctt tgtgcacaga atgtaactag 660
caagcccatt agcacccaga taattctatc atgttagttt cccatcctgg aaaatctttg 720
tacagtggga agttccccga tgtgtttttc tttcttaggt gaagggttgg ctatatcact 780
ttattgaatt ttgcattcct tagactttta aaatatacta atgtattcta gtcttactct 840
aaagaccttt gatgttaaag gaatccttca tttatttcat attccctatc tcatagggcc 900
acaattattt taatacagag atgattttca aaatatttta acaactggta caggacagat 960
gccagccact cagaagggat gcctgctgta aacaagcagt atgtatggtt gtaccaatgc 1020
ctattggctg aacattatgc tactttcaga tattaaaatg gtgttccttt gaatcgtg 1078

<210> 2

<211> 1713
<212> DNA
<213> Homo sapiens

<400> 2
atcgcattgc accaggatga ctctgaaatg gacttcagtt cttctgctga tacatctcca 60
gttgttactt tagctctggg agttgtggaa aagtgctggt gtgggccgca gaatacagcc 120
attggatgaa tatgaagaca atcctgaaag agcttgttca gagaggtcat gaggtgactg 180
tactggcatc ttcagcttcc attctttttg atcccaatga tgcatccact cttaaatttg 240
aagtttatcc tacatcttta actaaaactg aatttgagaa tatcatcatg caacaggtta 300
agagatggtc agacattcga aaagatagct tttggttata tttttcacaa gaacaagaaa 360
tcctgtggga attatatgac atatttagaa acttctgtaa agatgtagtt tcaaataaga 420
aagttatgaa aaaactacaa gagtcaagat ttgacatcgt ttttgcagat gctgtttttc 480
cctgtggtga gctgctggct gcgctactta acatacggtt tgtgtacagt ctccgcttta 540
ctcctggcta cacaattgaa aggcacagtg gaggactgat tttccctcct tcctacatac 600
ctattgttat gtcaaaatta agtgatcaaa tgactttcat ggagagggta aaaaatatga 660
tctatgtgct ttatttttgac ttttggttcc aaatgtctga tatgaagaag tgggatcagt 720
tttacagtga agttttagga agacccacta ccttatttga gacaatggga aaagctgaca 780
tatggcttat gcgaaactcc tggagttttc aatttcctca tccattctta ccaaacgttg 840
attttgttgg aggattccac tggcaaacct gccaaacccc tacctaagga aatggaggag 900
tttgtacaga gctctggaga aaatggtgtt gtggtgtttt ctctggggtc agtgataagt 960
aacatgacag cagaaagggc caatgtaatt gcaacagccc ttgccaagat cccacaaaag 1020
gttctgtgga gatttgatgg gaataaacca gatgccttag gtctcaatac tcggctgtat 1080
aagtggatac cccagaatga ccttctaggt catccaaaaa ccagagcttt tataactcat 1140
ggtggagcca atggcatcta tgaggcaatc taccatggga tccctatggt gggcattcca 1200
ttgttttggg atcaacctga taacattgct cacatgaagg ccaagggagc agctgttaga 1260
ttggacttca acacaatgtc gagtacagac ctgctgaatg cactgaagac agtaattaat 1320
gatcctttat ataaagagaa tattatgaaa ttatcaagaa ttcaacatga tcaaccagta 1380
aagcccctgg atcgagcagt cttctggatt gaatttgtca tgccccacaa aggagccaaa 1440
caccttcgag ttgcagccca tgacctcacc tggttccagt accactcttt ggatgtgatt 1500
gggtttctgc tggcctgtgt ggcaactgtg atatttatca tcacaaagtt ttgtctgttt 1560
tgtttctgga agtttgctag aaaagggaag aagggaaaaa gagattagtt atgtctgaca 1620
tttgaagctg gaaaaccaga tagataggac aacttcagtt tattccagca agaaagaaaa 1680
gattgttatg caagatttct ttcttcctgt gac 1713

<210> 3
<211> 2327
<212> DNA
<213> Homo sapiens

<220>
<221> unsure
<222> (924)

<220>
<221> unsure
<222> (1678)..(1704)

<400> 3
gatggatgca tctcaaaatg tatagccaga cttgagaggt gacaattaaa gatctaaaaa 60
agagaggaga ttcccccaaa caacaatatt taatttttctt agtaaaaaga ataacagaat 120
gcatcgtggc aatccttaag caacattatc tatgtggact gcttaaatca gcaaaacacc 180
agaagtttgg ttaacttggg caatatgaca agtattactt tttgggcaaa actactcatt 240
aagcaatttc tctagtgtgt cggacacaaa taggttcttt atttttggca tgtatgcctt 300
tttattttca ttcaattttt ttttttctc agacagacat agtagtaacg actagcattg 360
gaaaatacat atcactattc ttggaatatt tatggtcagt ctacttttta gtagaatatt 420
tttggatagc gttgacacga tagatcttat tccatacttc tttattattg ataatttat 480
tttcattttt tgctttcatt attatacata ttttggtgga gaagaggttg ggctttttg 540
aaagagacaa aaatttatta taacactaaa cactcctttt ttgacatatt aaagccttta 600
ttccatctct caagatatat ataaaattt attttttaa tttaagattt ctgaattatt 660
ttatcttaaa ttgtgatttt aaacgagcta ttatggtacg gaacttttt taatgaggaa 720
tttcatgatg atttaggaat tttctctctt ggaaaaggct tcccctgtga tgaaaatgat 780
gtgccagcta aaattgtgtg ccatttaaaa actgaaaata ttttaaaatt atttgtctat 840
attctaaatt gagctttgga tcaaacttta ggccaggacc agctcatgcg ttctcattct 900
tccttttctc actctttctc tcancactca cctctgtatt cattctgttg tttgggatag 960
aaaaatcata aagagccaac ccatctcaga acgttgtgga ttgagagaga cactacatga 1020
ctccaagtat atgagaaaag gacagagctc taattgataa ctctgtagtt caaaaggaaa 1080
agagtatgcc caattctctc tacatgacat attgagattt tttttaatca acttttaaga 1140
tagtgatgtt ctgttctaaa ctgttctgtt ttagtgaagg tagattttta taaaacaagc 1200
atggggattc ttttctaagg taatattaat gagaagggaa aaaagtatct ttaacagctc 1260
tttgttgaag cctgtggtag cacattatgt ttataattgc acatgtgcac ataatctatt 1320
atgatccaat gcaaatacag ctccaaaaat attaaatgta tatatatttt aaaatgcctg 1380
aggaaataca tttttcttaa taaactgaag agtctcagta tggctattaa aataattatt 1440
agcctcctgt tgtgtggctg caaaacatca caaagtgacc ggtcttgaga cctgtgaact 1500
gctgccctgt ttagtaaata aaattaatgc atttctagag ggggaatatc tgccatccag 1560
tggtggaaat gtggagtaaa gaagctggtg gtctgcttct gtgctgtatg ccagcctttt 1620
gccttaagtt gagaggaggt caactttagc tactgtcttt ggtttgagag ccatggcnnn 1680
nnnnnnnnnn nnnnnnnnnn nnnngtcgtc tttggtgagc cagtaaggtg aaagcttgct 1740
gactgtccaa ggcacaagag aaaattgagg aattgaaatg caacctgagt atcaaactaa 1800
atattctaat caaaggtagg tactgttagg tggaattcta tcagcaggca actgcaaatg 1860
agaagaagat agaaggacgc ccgtcgggac tttggagggc agtgttattt tcccaaagaa 1920
agacggccaa gggcagaggc atggattctt tgcagagcac ttccttttgg tttttcagta 1980
ctgtttcata gacagtgggc tcacatgttc ctgatagtgc tgcagttgct tagaaagcat 2040
cccagttatt gcagtaatta gaacttctgg aatatgctag ggcagaagta tgtcaagtat 2100
gtcacatgaa gaaaatgtga aattcaagag taatccacac gtgagaaact agacaatgta 2160
cattcatgtg ttctcttgaa aggaaaggga gagctgtaag cttcactctg tcctacaccg 2220
gagaaaagca ggaataactt taccgtggaa ataatgttta gcttttatgc agagaaaatt 2280
gtccttccta gagcatagag tcccaaaact caattctggt tttcccc 2327

<210> 4
<211> 639
<212> DNA
<213> Homo sapiens

<400> 4
ccagaaccga gtttaggtcc aggttctcgt tctggcaaat ctttctcctt accttcttcc 60

tccacccctc cacctatgcc atgttttccc ttagccactc cccagctcgg tggaggaaag 120
gcaggcctaa ctaggtaccg tcttcccgac tttgctcaat gatagctggg tgggtctagc 180
tgggttccag ccacttgtaa tgtgggacat ctctcacccc aactttgtag gtggagcaac 240
tgctacagag gtaaatatga ttaactttac attccatctt tcgtctgctc ccaaacttaa 300
cagcaggtaa tctgcttcta gcaagtggtg aaggtaagag aagcatctgt ataggaggca 360
agagatctga gtccttttga aggcctatcc tctgctctgt atctcaatta ctgttcttca 420
tttcaattat tcttacctac tattcagttc ccttgatctt ttcttcttgg gggctgtctt 480
agggtcaggg agattgcaga agcaccagaa ctaggagcag ccctgagaca tggggagttg 540
gagctgaagg aggaatggca ggatgaagaa ttccctaggt gaggacgtgt gagggtggct 600
gggagaaggg aggggtggtc acgaatggac ggaggggat 639

<210> 5
<211> 779
<212> DNA
<213> Homo sapiens

<400> 5
gtatacattc tttattaatc attttgcttc caaccccatt tagcctgcca ttgaaatgca 60
aaagtctgtt ccaaataaag ccttggaatt gaagaatgaa caaacattga gagcagatga 120
gatactccca tcagaatcca aacaaaagga ctatgaagaa agttcttggg attctgagag 180
tctctgtgag actgtttcac agaaggatgt gtgtttaccc aaggctacac atcaaaaaga 240
aatagataaa ataaatggaa aattagaagg gtctcctgtt aaagatggtc ttctgaaggc 300
taactgcgga atgaaagttt ctattccaac taaagcctta gaattgatgg acatgcaaac 360
tttcaaagca gagcctcccg agaagccatc tgccttcgag cctgccattg aaatgcaaaa 420
gtctgttcca aataaagcct tggaattgaa gaatgaacaa acattgagag cagatcagat 480
gttcccttca gaatcaaaac aaaagaaggt tgaagaaaat tcttgggatt ctgagagtct 540
ccgtgagact gtttcacaga aggatgtgtg tgtacccaag gctacacatc aaaaagaaat 600
ggataaaata agtggaaaat tagaagattc aactagccta tcaaaaatct tggatacagt 660
tcattcttgt gaaagagcaa gggaacttca aaaagatcac tgtgaacaac gtacaggaaa 720
aatggaacaa atgaaaaaga agttttgtgt actgaaaaag aaactgtcag aagcaaaaa 779

<210> 6
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 6
accccattta gcctgccat 19

<210> 7
<211> 24
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 7
atgggagtat ctcatctgct ctca 24

<210> 8
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 8
tgtttgttca ttcttcaatt ccaaggcttt 30

<210> 9
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 9
gcccattagc acccagataa t 21

<210> 10
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 10
gccaaccctt cacctaagaa a 21

<210> 11
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 11
cttcccactg tacaaagatt ttccaggatg 30

<210> 12
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 12
cctggagttt tcaatttcct ca 22

<210> 13
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 13
ccccagagaa aacaccacaa 20

<210> 14
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 14
actcctccat ttccttaggt aggggtttg 29

<210> 15
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 15
gagcacttcc ttttggtttt tc 22

<210> 16
<211> 23
<212> DNA

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 16
gccctagcat attccagaag ttc 23

<210> 17
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 17
tagacagtgg gctcacatgt tcctgatagt g 31

<210> 18
<211> 1722
<212> DNA
<213> Homo sapiens

<400> 18
tgcaccagga tgactctgaa atggacttca gttcttctgc tgatacatct cagttgttac 60
tttagctctg ggagttgtgg aaaagtgctg gtgtgggccg cagaatacag ccattggatg 120
aatatgaaga caatcctgaa agagcttgtt cagagaggtc atgaggtgac tgtactggca 180
tcttcagctt ccattctttt tgatcccaat gatgcatcca ctcttaaatt tgaagtttat 240
cctacatctt taactaaaac tgaatttgag aatatcatca tgcaacaggt taagagatgg 300
tcagacattc gaaaagatag cttttggtta tatttttcac aagaacaaga aatcctgtgg 360
gaattatatg acatatttag aaacttctgt aaagatgtag tttcaaataa gaaagttatg 420
aaaaaactac aagagtcaag atttgacatc gtttttgcag atgctgtttt tccctgtggt 480
gagctgctgg ctgcgctact taacatacgg tttgtgtaca gtctccgctt tactcctggc 540
tacacaattg aaaggcacag tggaggactg attttccctc cttcctacat acctattgtt 600
atgtcaaaat taagtgatca aatgactttc atggagaggg taaaaaatat gatctatgtg 660
ctttattttg acttttggtt ccaaatgtct gatatgaaga agtgggatca gttttacagt 720
gaagttttag gaagacccac taccttattt gagacaatgg gaaaagctga catatggctt 780
atgcgaaact cctggagttt tcaatttcct catccattct taccaaacgt tgattttgtt 840
ggaggattcc actgcaaacc tgccaaaccc ctacctaagg aaatggagga gtttgtacag 900
agctctggag aaaatggtgt tgtggtgttt tctctggggt cagtgataag taacatgaca 960
gcagaaaggg ccaatgtaat tgcaacagcc cttgccaaga tcccacaaaa ggttctgtgg 1020
agatttgacg ggaataaacc agatgcctta ggtctcaata ctcggctgta caagtggata 1080
ccccagaatg accttctagg tcatccaaaa accagagctt ttataactca tggtggagcc 1140
aatggcatct atgaggcaat ctaccatggg atccctatgg tgggcattcc attgtttttt 1200
gatcaacctg ataacattgc tcacatgaag gccaagggag cagctgttag attggacttc 1260
aacacaatgt cgagtacaga cctgctgaat gcactgaaga cagtaattaa tgatccttta 1320
tataaagaga atattatgaa attatcaaga attcaacatg atcaaccagt aaagcccctg 1380

gatcgagcag tcttctggat tgaatttgtc atgccccaca aaggagccaa acaccttcga 1440
gttgcagccc atgacctcac ctggttccag taccactctt tggatgtgat tgggtttctg 1500
ctggcctgtg tggcaactgt gatatttatc atcacaaagt tttgtctgtt ttgtttctgg 1560
aagtttgcta gaaaagggaa gaagggaaaa agagattagt tatgtctgac atttgaagct 1620
ggaaaaccag atagatagga caacttcagt ttattccagc aagaaagaaa agattgttat 1680
gcaagatttc tttcttcctg tgacaaaaaa aaaaaaaaaa aa 1722

<210> 19
<211> 529
<212> PRT
<213> Homo sapiens

<400> 19

Met	Thr	Leu	Lys	Trp	Thr	Ser	Val	Leu	Leu	Leu	Ile	His	Leu	Ser	Cys
1				5				10					15		
Tyr	Phe	Ser	Ser	Gly	Ser	Cys	Gly	Lys	Val	Leu	Val	Trp	Ala	Ala	Glu
			20					25				30			
Tyr	Ser	His	Trp	Met	Asn	Met	Lys	Thr	Ile	Leu	Lys	Glu	Leu	Val	Gln
		35					40					45			
Arg	Gly	His	Glu	Val	Thr	Val	Leu	Ala	Ser	Ser	Ala	Ser	Ile	Leu	Phe
	50					55					60				
Asp	Pro	Asn	Asp	Ala	Ser	Thr	Leu	Lys	Phe	Glu	Val	Tyr	Pro	Thr	Ser
65					70					75					80
Leu	Thr	Lys	Thr	Glu	Phe	Glu	Asn	Ile	Ile	Met	Gln	Gln	Val	Lys	Arg
				85					90					95	
Trp	Ser	Asp	Ile	Arg	Lys	Asp	Ser	Phe	Trp	Leu	Tyr	Phe	Ser	Gln	Glu
			100					105					110		
Gln	Glu	Ile	Leu	Trp	Glu	Leu	Tyr	Asp	Ile	Phe	Arg	Asn	Phe	Cys	Lys
		115					120					125			
Asp	Val	Val	Ser	Asn	Lys	Lys	Val	Met	Lys	Lys	Leu	Gln	Glu	Ser	Arg
	130					135					140				
Phe	Asp	Ile	Val	Phe	Ala	Asp	Ala	Val	Phe	Pro	Cys	Gly	Glu	Leu	Leu
145					150					155					160
Ala	Ala	Leu	Leu	Asn	Ile	Arg	Phe	Val	Tyr	Ser	Leu	Arg	Phe	Thr	Pro
				165					170					175	
Gly	Tyr	Thr	Ile	Glu	Arg	His	Ser	Gly	Gly	Leu	Ile	Phe	Pro	Pro	Ser
			180					185					190		

Tyr Ile Pro Ile Val Met Ser Lys Leu Ser Asp Gln Met Thr Phe Met
195 200 205

Glu Arg Val Lys Asn Met Ile Tyr Val Leu Tyr Phe Asp Phe Trp Phe
210 215 220

Gln Met Ser Asp Met Lys Lys Trp Asp Gln Phe Tyr Ser Glu Val Leu
225 230 235 240

Gly Arg Pro Thr Thr Leu Phe Glu Thr Met Gly Lys Ala Asp Ile Trp
245 250 255

Leu Met Arg Asn Ser Trp Ser Phe Gln Phe Pro His Pro Phe Leu Pro
260 265 270

Asn Val Asp Phe Val Gly Gly Phe His Cys Lys Pro Ala Lys Pro Leu
275 280 285

Pro Lys Glu Met Glu Glu Phe Val Gln Ser Ser Gly Glu Asn Gly Val
290 295 300

Val Val Phe Ser Leu Gly Ser Val Ile Ser Asn Met Thr Ala Glu Arg
305 310 315 320

Ala Asn Val Ile Ala Thr Ala Leu Ala Lys Ile Pro Gln Lys Val Leu
325 330 335

Trp Arg Phe Asp Gly Asn Lys Pro Asp Ala Leu Gly Leu Asn Thr Arg
340 345 350

Leu Tyr Lys Trp Ile Pro Gln Asn Asp Leu Leu Gly His Pro Lys Thr
355 360 365

Arg Ala Phe Ile Thr His Gly Gly Ala Asn Gly Ile Tyr Glu Ala Ile
370 375 380

Tyr His Gly Ile Pro Met Val Gly Ile Pro Leu Phe Phe Asp Gln Pro
385 390 395 400

Asp Asn Ile Ala His Met Lys Ala Lys Gly Ala Ala Val Arg Leu Asp
405 410 415

Phe Asn Thr Met Ser Ser Thr Asp Leu Leu Asn Ala Leu Lys Thr Val
420 425 430

Ile Asn Asp Pro Leu Tyr Lys Glu Asn Ile Met Lys Leu Ser Arg Ile
435 440 445

```
Gln His Asp Gln Pro Val Lys Pro Leu Asp Arg Ala Val Phe Trp Ile
    450                 455                 460

Glu Phe Val Met Pro His Lys Gly Ala Lys His Leu Arg Val Ala Ala
465                 470                 475                 480

His Asp Leu Thr Trp Phe Gln Tyr His Ser Leu Asp Val Ile Gly Phe
                485                 490                 495

Leu Leu Ala Cys Val Ala Thr Val Ile Phe Ile Ile Thr Lys Phe Cys
            500                 505                 510

Leu Phe Cys Phe Trp Lys Phe Ala Arg Lys Gly Lys Lys Gly Lys Arg
        515                 520                 525

Asp
```

<210> 20
<211> 10006
<212> DNA
<213> Homo sapiens

<400> 20
ttcctccgcg aaggctcctt tgatattaat agtgttggtg tcttgaaact gacgtaatgc 60
gcggagactg aggtcctgac aagcgataac atttctgata aagacccgat cttactgcaa 120
tctctagcgt cctcttttt ggtgctgctg gtttctccag acctcgcgtc ctctcgattg 180
ctctctcgcc ttcctatttc ttttttttt ttttaaacaa aaaacaacac cccctcccct 240
ctcccacccg gcaccgggca catccttgct ctatttcctt tctctttctc tctctctctc 300
tctctttttt aataagggtg ggggagggaa agggggggga ggcaggaaag acctttttct 360
ctccccccg caataatcca agatcaactc tgcaaacaac agaagacggt tcatggcttt 420
ggccgccgcg ccaccatctt tcgggctgcc gagggtgttc ttgacgatta atcaacagat 480
gtacagatca gctctcaaaa tgtcttctgt gtcttctgag cgtcttctaa gacaattgca 540
ttagcctcct gctagttgac taatagaatt aataattgta aaaagcactc taaagccaca 600
tgccttatga agtcaatgct gggtatgatt ttacaaatat ggtccggaaa aagaaccccc 660
ctctgagaaa cgttgcaagt gaaggcgagg gccagatcct ggagcctata ggtacagaaa 720
gcaaggtatc tggaaagaac aaagaattct ctgcagatca gatgtcagaa aatacggatc 780
agagtgatgc tgcagaacta aatcataagg aggaacatag cttgcatgtt caagatccat 840
cttctagcag taagaaggac ttgaaaagcg cagttctgag tgagaaggct ggcttcaatt 900
atgaaagccc cagtaaggga ggaaactttc cctcctttcc gcatgatgag gtgacagaca 960
gaaatatgtt ggctttctca tttccagctg ctgggggagt ctgtgagccc ttgaagtctc 1020
cgcaaagagc agaggcagat gaccctcaag atatggcctg cacccctca ggggactcac 1080
tggagacaaa ggaagatcag aagatgtcac caaaggctac agaggaaaca gggcaagcac 1140
agagtggtca agccaattgt caaggtttga gcccagtttc agtggcctca aaaaacccac 1200
aagtgccttc agatgggggt gtaagactga ataaatccaa aactgactta ctggtgaatg 1260
acaacccaga cccggcacct ctgtctccag agcttcagga ctttaaatgc aatatctgtg 1320

gatatggtta ctacggcaac gaccccacag atctgattaa gcacttccga aagtatcact 1380
taggactgca taaccgcacc aggcaagatg ctgagctgga cagcaaaatc ttggcccttc 1440
ataacatggt gcagttcagc cattccaaag acttccagaa ggtcaaccgt tctgtgtttt 1500
ctggtgtgct gcaggacatc aattcttcaa ggcctgtttt actaaatggg acctatgatg 1560
tgcaggtgac ttcaggtgga acattcattg gcattggacg gaaaacacca gattgccaag 1620
ggaacaccaa gtatttccgc tgtaaattct gcaatttcac ttatatgggc aactcatcca 1680
ccgaattaga acaacatttt cttcagactc acccaaacaa aataaaagct tctctcccct 1740
cctctgaggt tgcaaaacct tcagagaaaa actctaacaa gtccatccct gcacttcaat 1800
ccagtgattc tggagacttg ggaaaatggc aggacaagat aacagtcaaa gcaggagatg 1860
acactcctgt tgggtactca gtgcccataa agcccctcga ttcctctaga caaaaggtac 1920
agaggccacc agttactact ggtgtaaatt ttgtagtttc agctgtgagt catctagctc 1980
acttaaactg ctagaacatt atggcaagca gcacggagca gtgcagtcag gcggccttaa 2040
tccagagtta aatgataagc tttccagggg ctctgtcatt aatcagaatg atctagccaa 2100
aagttcagaa ggagagacaa tgaccaagac agacaagagc tcgagtgggg ctaaaaagaa 2160
ggacttctcc agcaagggag ccgaggataa tatggtaacg agctataatt gtcagttctg 2220
tgacttccga tattccaaaa gccatggccc tgatgtaatt gtagtggggc cacttctccg 2280
tcattatcaa cagctccata acattcacaa gtgtaccatt aaacactgtc cattctgtcc 2340
cagaggactt tgcagcccag aaaagcacct tggagaaatt acttatccgt ttgcttgtag 2400
aaaaagtaat tgttcccact gtgcactctt gcttctgcac ttgtctcctg gggcggctgg 2460
aagctcgcga gtcaaacatc agtgccatca gtgttcattc accacccctg acgtagatgt 2520
actcctcttt cactatgaaa gtgtgcatga gtcccaagca tcggatgtca aacaagaagc 2580
aaatcacctg caaggatcgg atgggcagca gtctgtcaag gaaagcaaag aacactcatg 2640
taccaaatgt gattttatta cccaagtgga agaagagatt tcccgacact acaggagagc 2700
acacagctgc tacaaatgcc gtcagtgcag ttttacagct gccgatactc agtcactact 2760
ggagcacttc aacactgttc actgccagga acaggacatc actacagcca acggcgaaga 2820
ggacggtcat gccatatcca ccatcaaaga ggagcccaaa attgacttca gggtctacaa 2880
tctgctaact ccagactcta aaatgggaga gccagtttct gagagtgtgg tgaagagaga 2940
gaagctggaa gagaaggacg ggctcaaaga gaaagtttgg accgagagtt ccagtgatga 3000
ccttcgcaat gtgacttgga gaggggcaga catcctgcgg gggagtccgt catacaccca 3060
agcaagcctg gggctgctga cgcctgtgtc tggcacccaa gagcagacaa agactctaag 3120
ggatagtccc aatgtggagg ccgcccatct ggcgcgacct atttatggct tggctgtgga 3180
aaccaaggga ttcctgcagg gggcgccagc tggcggagag aagtctgggg ccctccccca 3240
gcagtatcct gcatcgggag aaaacaagtc caaggatgaa tcccagtccc tgttacggag 3300
gcgtagaggc tccggtgttt tttgtgccaa ttgcctgacc acaaagacct ctctctggcg 3360
aaagaatgca aatggcggat atgtatgcaa cgcgtgtggc ctctaccaga agcttcactc 3420
gactcccagg cctttaaaca tcattaaaca aaacaacggt gagcagatta ttaggaggag 3480
aacaagaaag cgccttaacc cagaggcact tcaggctgag cagctcaaca aacagcagag 3540
gggcagcaat gaggagcaag tcaatggaag cccgttagag aggaggtcag aagatcatct 3600
aactgaaagt caccagagag aaattccact ccccagccta agtaaatacg aagcccaggg 3660
ttcattgact aaaagccatt ctgctcagca gccagtcctg gtcagccaaa ctctggatat 3720
tcacaaaagg atgcaacctt tgcacattca gataaaaagt cctcaggaaa gtactggaga 3780
tccaggaaat agttcatccg tatctgaagg gaaaggaagt tctgagagag gcagtcctat 3840
agaaaagtac atgagacctg cgaaacaccc aaattattca ccaccaggca gccctattga 3900
aaagtaccag tacccacttt ttggacttcc cttttacata atgacttcca gagtgaagct 3960
gattggctgc ggttctggag taaatataag ctctccgttc ctgggaatcc gcactacttg 4020
agtcacgtgc ctggcctacc aaatccttgc caaaactatg tgccttatcc caccttcaat 4080
ctgcctcctc atttttcagc tgttggatca gacaatgaca ttcctctaga tttggcgatc 4140
aagcattcca gacctgggcc aactgcaaac ggtgcctcca aggagaaaac gaaggcacca 4200

ccaaatgtaa aaaatgaagg tcccttgaat gtagtaaaaa cagagaaagt tgatagaagt 4260
actcaagatg aactttcaac aaaatgtgtg cactgtggca ttgtctttct ggatgaagtg 4320
atgtatgctt tgcatatgag ttgccatggt gacagtggac ctttccagtg cagcatatgc 4380
cagcatcttt gcacggacaa atatgacttc acaacacata tccagagggg cctgcatagg 4440
aacaatgcac aagtggaaaa aaatggaaaa cctaaagagt aaaaccttag cacttagcac 4500
aattaaatag aaataggttt tcttgatggg aattcaatag cttgtaatgt cttatgaaga 4560
cctattaaaa aaatacttca tagagcctgc cttatccaac atgaaattcc cttcttttgt 4620
tattctttct tttgatgagt aggttaccaa gattaaaaag tgagataaat ggtcaatgag 4680
aaagaatgga agatggtaaa caatcacttt ttaaaacctg ttaagtcaaa accatcttgg 4740
ctaatatgta ctggggaaat aatccataag agatatcacc agactagaat taatatattt 4800
ataaagaaag agaccaaaac tgtctagaat ttgaaagggt ttacatatta ttatactaaa 4860
gcagtactgg actggccatt ggaccatttg ttccaaaacc cataaattgt tgcctaaatt 4920
tataatgatc atgaaaccct aggcagagga ggagaaattg aaggtccagg gcaatgaaag 4980
aaaaatggcg ccctctcaat ttagtcttct ctcattggcc atgtttcaga ttttgaccta 5040
gaaatgcgag ctgtggttag gcttggttag agtgcagcaa gcaacatgac agatggtggc 5100
acgctgtttt tacccagccc tgcctgtaca tacacatgca caccctctct gatatttttg 5160
tcctttagat gttcaaatac tcagtagtcc ttttgtttgc ggtttagatt cattttgtcc 5220
acacatgtac ccattttaaa aaacaatgtc ctcgatgctt ctgtagtgat ttcattttag 5280
ccaggtattt ctttcttgtg tgtgatgaac cagtatggat ttgcttttct aagcctcctg 5340
ttggttacta atctcacttg gcacattata actaaaggaa tcccctcaat tcaaaagcat 5400
agatggatac aaatgtcaga ccgtgggttt aatttgttta gaacacatgg catttcttca 5460
caaggtaacc tgctgtattt atttattttc ttttggttaa atataatttc caaactttgt 5520
ggtcaggcag cgtctaaggt tacgttacca cagactgaca gttggtatat gtaccagcca 5580
atcccttcat taaatgtata cagatttagt taagtagcat taaataggat tcttagaagt 5640
atgtcctcat agaactttta atacttaagg ctttgtaaaa actatccatg aagggaaagc 5700
tcctcagcat aactgctcag ggaaataggg ctaaataact gaacattaaa taattggtta 5760
aaggtgctgt tagtcgagcc tcaatgcttg ctacaaggat gtatgtacaa ggactgactt 5820
taataatttg cattatattg tcccaaccag tagtttattt tttgccacgg agatgtagaa 5880
gatattacaa gctactggat gcactgtcag attaacttat ttcattaaag aagttgggag 5940
aacaaatagg aaaaaaaaac ttatttttct agtaaatatt aatgtattac atttcaaata 6000
atggtgcctg acatattgaa taattatttt ctacagtgta cgtatgcaac aaagatattc 6060
catcatgcat tagagtcagt tctggctctg cctagctgtt tacatttgca aatgtagcaa 6120
acaaggtaat gaagcaacta tttctattgc agtagatatc cttttgtgtg tgtgtgtgtg 6180
cattaaagtt gtaaacggta acatgaaaca aatgaaagtt cttgctataa tggtatggaa 6240
aacaagaagg aaatgaaaat atttttatgc ctacttagga aaaaaagggt agcacttatt 6300
cattccaagt actttttttt ttttaatttt taagctctta actcacattg ttatgcttaa 6360
gatgataaac atatatcctc tttttattgc tttgtctatg tttcatatga aacatttcag 6420
aaattatttt gataagtgtt gctggaatct gcaacgctga tttttttttg cattctgtag 6480
tcgcatttgc actccatttt tacattaatt cgcagttgct ttgtatcatt gttttgtttg 6540
ggttttgttt ctttttcaca gtgccgggtc ttcgtttctt aaagttggat ggcaggtaga 6600
gttcaaccag ttcgtgactg ttgtagcgaa tgaagttaaa aaaatgtctt tctgatgttg 6660
tgttgtcatt ttcatttttg catttttttg tttgcatatt aaaaaaagag aaaagagaaa 6720
gcaagagaca gaaatcagga ctaagtcctc tgcttcagtt tcattgttaa cgggccttat 6780
tctgatctca cctgtcgcgt agctctaata ttcacataaa ctgaaataaa gaagtggaat 6840
gaggagcttt gacattcaaa ttatgtgatg taatttatct tccttaggaa ttttgatgga 6900
tgcatctcaa aatgtatagc cagacttgag aggtgacaat taaagatcta aaaaagagag 6960
gagattcccc caaacaacaa tatttaattt tcttagtaaa aagaataaca gaatgcatcg 7020
tggcaatcct taagcaacat tatctatgtg gactgcttaa atcagcaaaa caccagaagt 7080

ttggttaact tgggcaatat gacaagtatt acttttggg caaaactact cattaagcaa 7140
tttctctagt gtgtcggaca caaataggtt ctttatttt ggcatgtatg ccttttatt 7200
ttcattcaat ttttttttt tctcagacag acatagtagt atcaactagc attggaaaat 7260
acatatcact attcttggaa tatttatggt cagtctactt tttagtaaaa tatttttgga 7320
tagcgttgac acgatagatc ttattccata cttctttatt attgataatt ttatttttcat 7380
tttttgcttt cattattata catattttgg tggagaagag gttgggcttt tttgaaagag 7440
acaaaaattt attataacac taaacactcc ttttttgaca tattaaagcc tttattccat 7500
ctctcaagat atattataaa atttatttt ttaatttaag atttctgaat tattttatct 7560
taaattgtga ttttaaacga gctattatgg tacggaactt tttttaatga ggaatttcat 7620
gatgatttag gaatttttctc tcttggaaaa ggcttcccct gtgatgaaaa tgatgtgcca 7680
gctaaaattg tgtgccattt aaaaactgaa aatattttaa aattatttgt ctatattcta 7740
aattgagctt tggatcaaac tttaggccag gaccagctca tgcgttctca ttcttccttt 7800
tctcactctt tctctcatca ctcacctctg tattcattct gttgtttggg atagaaaaat 7860
cataaagagc caacccatct cagaacgttg tggattgaga gagacactac atgactccaa 7920
gtatatgaga aaaggacaga gctctaattg ataactctgt agttcaaaag gaaagagtat 7980
gcccaattct ctctacatga catattgaga tttttttaa tcaactttta agatagtgat 8040
gttctgttct aaactgttct gttttagtga aggtagattt ttataaaaca agcatgggga 8100
ttcttttcta aggtaatatt aatgagaagg gaaaaaagta tctttaacag ctctttgttg 8160
aagcctgtgg tagcacatta tgtttataat tgcacatgtg cacataatct attatgatcc 8220
aatgcaaata cagctccaaa aatattaaat gtatatatat tttaaaatgc ctgaggaaat 8280
acatttttct taataaactg aagagtctca gtatggctat taaaataatt attagcctcc 8340
tgttgtgtgg ctgcaaaaca tcacaaagtg accggtcttg agacctgtga actgctgccc 8400
tgtttagtaa ataaaattaa tgcatttcta gaggggggaat atctgccatc cagtggtgga 8460
aatgtggagt aaagaagctg gtggtctgct tctgtgctgt atgccagcct tttgccttaa 8520
gttgagagga ggtcaacttt agctactgtc tttggtttga gagccatggc aaaaaaaaaa 8580
aaagaaaaaa agatcaagtc gtctttggtg agccagtaag gtgaaagctt gctgactgtc 8640
caaggcacaa gagaaaattg aggaattgaa atgcaacctg agtatcaaac taaatattct 8700
aatcaaaggt aggtactgtt aggtggaatt ctatcagcag gcaactgcaa atgagaagaa 8760
gatagaagga cgcccgtcgg gactttggag ggcattgtta ttttcccaaa gaaagacggc 8820
caagggcaga ggcatggatt ctttgcagag cacttccttt tggtttttca gtactgtttc 8880
atagacagtg ggctcacatg ttcctgatag tgctgcagtt gcttagaaag catcccagtt 8940
aattgcagta attagaactt ctggaatatg ctagggcaga agtatgtcaa gtatgtcaca 9000
tgaagaaaat gtgaaattca agagtaatcc acacgtgaga aactagacaa tgtacattca 9060
tgtgttctct tgaaaggaaa gggagagctg taagcttcac tctgtcctac accggagaaa 9120
agcaggaata actttaccgt ggaaataatg tttagctttt atcagagaaa attgtccttc 9180
tagagcatag agtcccaaaa ctcaattctg gttttccccct gttttttttt ttttttttt 9240
tcccaacata tgaactgcag catatcactt tttctttttg tgcctcaggt tcctcacctg 9300
taaaattgaa aaatatatgt attaataata ttattaataa taataatggt aatgtagtac 9360
ttgtttgtaa agcactttga gatccttggt tgaaaggcac cataggagtg ccaagtatta 9420
ttatgtggcc aaggggggtta tttaaactgt cagttcccaa aggccaggaa aggttggggt 9480
cattttttctt aaagacgagc tgtaaatatc aactaggcag ccaatagtgt tgactatgaa 9540
gatgcaaaac tattactagg ctgataaaat catagtttct taatggctac caataaggca 9600
aatatcacaa taataaacgc caaattcctt agggcggact atttgacaac cacatggaaa 9660
actttggggg aggcatgagg ggggaacatc tcaaaatgcc aatgtaaaat ttaacttaca 9720
gcaatattca ccagcagaaa atgtctttca tatggaatga tttcatgttg ctaagaaaaa 9780
gaattcaatt tgtagtcctg atttgaatac tagaatgttg gctataatag ttctgttctt 9840
acaacacatg aaatttttttc gttttatttt attttgtttt catagtgcat gttcatttct 9900
actcacaaac atgttcttgg tgtatttctt atgcaaacaa tcttcaggca gcaaagatgt 9960

ctgttacatc taaacttgaa taataaagtt ttccaccagt tacaca 10006

<210> 21
<211> 1281
<212> PRT
<213> Homo sapiens

<400> 21

```
Met Val Arg Lys Lys Asn Pro Pro Leu Arg Asn Val Ala Ser Glu Gly
  1               5                  10                  15

Glu Gly Gln Ile Leu Glu Pro Ile Gly Thr Glu Ser Lys Val Ser Gly
             20                  25                  30

Lys Asn Lys Glu Phe Ser Ala Asp Gln Met Ser Glu Asn Thr Asp Gln
         35                  40                  45

Ser Asp Ala Ala Glu Leu Asn His Lys Glu Glu His Ser Leu His Val
     50                  55                  60

Gln Asp Pro Ser Ser Ser Ser Lys Lys Asp Leu Lys Ser Ala Val Leu
 65                  70                  75                  80

Ser Glu Lys Ala Gly Phe Asn Tyr Glu Ser Pro Ser Lys Gly Gly Asn
                 85                  90                  95

Phe Pro Ser Phe Pro His Asp Glu Val Thr Asp Arg Asn Met Leu Ala
            100                 105                 110

Phe Ser Phe Pro Ala Ala Gly Gly Val Cys Glu Pro Leu Lys Ser Pro
        115                 120                 125

Gln Arg Ala Glu Ala Asp Asp Pro Gln Asp Met Ala Cys Thr Pro Ser
    130                 135                 140

Gly Asp Ser Leu Glu Thr Lys Glu Asp Gln Lys Met Ser Pro Lys Ala
145                 150                 155                 160

Thr Glu Glu Thr Gly Gln Ala Gln Ser Gly Gln Ala Asn Cys Gln Gly
                165                 170                 175

Leu Ser Pro Val Ser Val Ala Ser Lys Asn Pro Gln Val Pro Ser Asp
            180                 185                 190

Gly Gly Val Arg Leu Asn Lys Ser Lys Thr Asp Leu Leu Val Asn Asp
        195                 200                 205

Asn Pro Asp Pro Ala Pro Leu Ser Pro Glu Leu Gln Asp Phe Lys Cys
```

```
    210                 215                 220

Asn Ile Cys Gly Tyr Gly Tyr Tyr Gly Asn Asp Pro Thr Asp Leu Ile
225                 230                 235                 240

Lys His Phe Arg Lys Tyr His Leu Gly Leu His Asn Arg Thr Arg Gln
                245                 250                 255

Asp Ala Glu Leu Asp Ser Lys Ile Leu Ala Leu His Asn Met Val Gln
            260                 265                 270

Phe Ser His Ser Lys Asp Phe Gln Lys Val Asn Arg Ser Val Phe Ser
        275                 280                 285

Gly Val Leu Gln Asp Ile Asn Ser Ser Arg Pro Val Leu Leu Asn Gly
    290                 295                 300

Thr Tyr Asp Val Gln Val Thr Ser Gly Gly Thr Phe Ile Gly Ile Gly
305                 310                 315                 320

Arg Lys Thr Pro Asp Cys Gln Gly Asn Thr Lys Tyr Phe Arg Cys Lys
                325                 330                 335

Phe Cys Asn Phe Thr Tyr Met Gly Asn Ser Ser Thr Glu Leu Glu Gln
            340                 345                 350

His Phe Leu Gln Thr His Pro Asn Lys Ile Lys Ala Ser Leu Pro Ser
        355                 360                 365

Ser Glu Val Ala Lys Pro Ser Glu Lys Asn Ser Asn Lys Ser Ile Pro
    370                 375                 380

Ala Leu Gln Ser Ser Asp Ser Gly Asp Leu Gly Lys Trp Gln Asp Lys
385                 390                 395                 400

Ile Thr Val Lys Ala Gly Asp Asp Thr Pro Val Gly Tyr Ser Val Pro
                405                 410                 415

Ile Lys Pro Leu Asp Ser Ser Arg Gln Asn Gly Thr Glu Ala Thr Ser
            420                 425                 430

Tyr Tyr Trp Cys Lys Phe Cys Ser Phe Ser Cys Glu Ser Ser Ser Ser
        435                 440                 445

Leu Lys Leu Leu Glu His Tyr Gly Lys Gln His Gly Ala Val Gln Ser
    450                 455                 460

Gly Gly Leu Asn Pro Glu Leu Asn Asp Lys Leu Ser Arg Gly Ser Val
```

```
465                 470                 475                 480

Ile Asn Gln Asn Asp Leu Ala Lys Ser Ser Glu Gly Glu Thr Met Thr
                485                 490                 495

Lys Thr Asp Lys Ser Ser Ser Gly Ala Lys Lys Lys Asp Phe Ser Ser
            500                 505                 510

Lys Gly Ala Glu Asp Asn Met Val Thr Ser Tyr Asn Cys Gln Phe Cys
        515                 520                 525

Asp Phe Arg Tyr Ser Lys Ser His Gly Pro Asp Val Ile Val Val Gly
    530                 535                 540

Pro Leu Leu Arg His Tyr Gln Gln Leu His Asn Ile His Lys Cys Thr
545                 550                 555                 560

Ile Lys His Cys Pro Phe Cys Pro Arg Gly Leu Cys Ser Pro Glu Lys
                565                 570                 575

His Leu Gly Glu Ile Thr Tyr Pro Phe Ala Cys Arg Lys Ser Asn Cys
            580                 585                 590

Ser His Cys Ala Leu Leu Leu Leu His Leu Ser Pro Gly Ala Ala Gly
        595                 600                 605

Ser Ser Arg Val Lys His Gln Cys His Gln Cys Ser Phe Thr Thr Pro
    610                 615                 620

Asp Val Asp Val Leu Leu Phe His Tyr Glu Ser Val His Glu Ser Gln
625                 630                 635                 640

Ala Ser Asp Val Lys Gln Glu Ala Asn His Leu Gln Gly Ser Asp Gly
                645                 650                 655

Gln Gln Ser Val Lys Glu Ser Lys Glu His Ser Cys Thr Lys Cys Asp
            660                 665                 670

Phe Ile Thr Gln Val Glu Glu Glu Ile Ser Arg His Tyr Arg Arg Ala
        675                 680                 685

His Ser Cys Tyr Lys Cys Arg Gln Cys Ser Phe Thr Ala Ala Asp Thr
    690                 695                 700

Gln Ser Leu Leu Glu His Phe Asn Thr Val His Cys Gln Glu Gln Asp
705                 710                 715                 720

Ile Thr Thr Ala Asn Gly Glu Glu Asp Gly His Ala Ile Ser Thr Ile
```

725 730 735

Lys Glu Glu Pro Lys Ile Asp Phe Arg Val Tyr Asn Leu Leu Thr Pro
740 745 750

Asp Ser Lys Met Gly Glu Pro Val Ser Glu Ser Val Val Lys Arg Glu
755 760 765

Lys Leu Glu Glu Lys Asp Gly Leu Lys Glu Lys Val Trp Thr Glu Ser
770 775 780

Ser Ser Asp Asp Leu Arg Asn Val Thr Trp Arg Gly Ala Asp Ile Leu
785 790 795 800

Arg Gly Ser Pro Ser Tyr Thr Gln Ala Ser Leu Gly Leu Leu Thr Pro
805 810 815

Val Ser Gly Thr Gln Glu Gln Thr Lys Thr Leu Arg Asp Ser Pro Asn
820 825 830

Val Glu Ala Ala His Leu Ala Arg Pro Ile Tyr Gly Leu Ala Val Glu
835 840 845

Thr Lys Gly Phe Leu Gln Gly Ala Pro Ala Gly Gly Glu Lys Ser Gly
850 855 860

Ala Leu Pro Gln Gln Tyr Pro Ala Ser Gly Glu Asn Lys Ser Lys Asp
865 870 875 880

Glu Ser Gln Ser Leu Leu Arg Arg Arg Arg Gly Ser Gly Val Phe Cys
885 890 895

Ala Asn Cys Leu Thr Thr Lys Thr Ser Leu Trp Arg Lys Asn Ala Asn
900 905 910

Gly Gly Tyr Val Cys Asn Ala Cys Gly Leu Tyr Gln Lys Leu His Ser
915 920 925

Thr Pro Arg Pro Leu Asn Ile Ile Lys Gln Asn Asn Gly Glu Gln Ile
930 935 940

Ile Arg Arg Arg Thr Arg Lys Arg Leu Asn Pro Glu Ala Leu Gln Ala
945 950 955 960

Glu Gln Leu Asn Lys Gln Gln Arg Gly Ser Asn Glu Glu Gln Val Asn
965 970 975

Gly Ser Pro Leu Glu Arg Arg Ser Glu Asp His Leu Thr Glu Ser His

980 985 990

Gln Arg Glu Ile Pro Leu Pro Ser Leu Ser Lys Tyr Glu Ala Gln Gly
995 1000 1005

Ser Leu Thr Lys Ser His Ser Ala Gln Gln Pro Val Leu Val Ser Gln
1010 1015 1020

Thr Leu Asp Ile His Lys Arg Met Gln Pro Leu His Ile Gln Ile Lys
1025 1030 1035 1040

Ser Pro Gln Glu Ser Thr Gly Asp Pro Gly Asn Ser Ser Ser Val Ser
1045 1050 1055

Glu Gly Lys Gly Ser Ser Glu Arg Gly Ser Pro Ile Glu Lys Tyr Met
1060 1065 1070

Arg Pro Ala Lys His Pro Asn Tyr Ser Pro Pro Gly Ser Pro Ile Glu
1075 1080 1085

Lys Tyr Gln Tyr Pro Leu Phe Gly Leu Pro Phe Val His Asn Asp Phe
1090 1095 1100

Gln Ser Glu Ala Asp Trp Leu Arg Phe Trp Ser Lys Tyr Lys Leu Ser
1105 1110 1115 1120

Val Pro Gly Asn Pro His Tyr Leu Ser His Val Pro Gly Leu Pro Asn
1125 1130 1135

Pro Cys Gln Asn Tyr Val Pro Tyr Pro Thr Phe Asn Leu Pro Pro His
1140 1145 1150

Phe Ser Ala Val Gly Ser Asp Asn Asp Ile Pro Leu Asp Leu Ala Ile
1155 1160 1165

Lys His Ser Arg Pro Gly Pro Thr Ala Asn Gly Ala Ser Lys Glu Lys
1170 1175 1180

Thr Lys Ala Pro Pro Asn Val Lys Asn Glu Gly Pro Leu Asn Val Val
1185 1190 1195 1200

Lys Thr Glu Lys Val Asp Arg Ser Thr Gln Asp Glu Leu Ser Thr Lys
1205 1210 1215

Cys Val His Cys Gly Ile Val Phe Leu Asp Glu Val Met Tyr Ala Leu
1220 1225 1230

His Met Ser Cys His Gly Asp Ser Gly Pro Phe Gln Cys Ser Ile Cys

1235 1240 1245

Gln His Leu Cys Thr Asp Lys Tyr Asp Phe Thr Thr His Ile Gln Arg
1250 1255 1260

Gly Leu His Arg Asn Asn Ala Gln Val Glu Lys Asn Gly Lys Pro Lys
1265 1270 1275 1280

Glu

Substitute Sheet (Rule 26)